



**HAL**  
open science

## In-host evolution of *Yersinia enterocolitica* during a chronic human infection

Savin Cyril, Pierre Lê-Bury, Julien Guglielmini, Thibaut Douché, Rodolphe Buzelé, Cécile Le Brun, Frédéric Bastides, François Maud, Béatrice Birmelé, Laura Guichard, et al.

► **To cite this version:**

Savin Cyril, Pierre Lê-Bury, Julien Guglielmini, Thibaut Douché, Rodolphe Buzelé, et al.. In-host evolution of *Yersinia enterocolitica* during a chronic human infection. 2024. pasteur-04610804

**HAL Id: pasteur-04610804**

**<https://pasteur.hal.science/pasteur-04610804v1>**

Preprint submitted on 13 Jun 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

1 **In-host evolution of *Yersinia enterocolitica* during a chronic human infection**

2

3 **Running title:** Human yersiniosis in-host evolution

4

5 **Authors:**

6 SAVIN Cyril\*<sup>#1,2</sup>, LÊ-BURY Pierre<sup>#1,3</sup>, GUGLIELMINI Julien<sup>4</sup>, DOUCHÉ Thibaut<sup>5</sup>, BUZELÉ Rodolphe<sup>¶6,7</sup>, LE  
7 BRUN Cécile<sup>6</sup>, BASTIDES Frédéric<sup>7</sup>, FRANÇOIS Maud<sup>8</sup>, BIRMELE Béatrice<sup>8</sup>, GUICHARD Laura<sup>1,2</sup>,  
8 CABANEL Nicolas<sup>1,2</sup>, DORTET Laurent<sup>3,9,10</sup>, MATONDO Mariette<sup>5</sup>, DUSSURGET Olivier<sup>1</sup>, CARNIEL  
9 Elisabeth<sup>1,2</sup>, LANOTTE Philippe<sup>#6,11</sup>, PIZARRO-CERDÁ Javier\*<sup>#1,2</sup>

10

11 **Affiliations:**

12 <sup>1</sup>Institut Pasteur, Université Paris Cité, *Yersinia* Research Unit, WHO Collaborating Research and  
13 Reference Centre for Plague FRA-146, F-75015 Paris, France

14 <sup>2</sup>Institut Pasteur, Université Paris Cité, *Yersinia* National Reference Laboratory, F-75015 Paris, France

15 <sup>3</sup>Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-  
16 HB/IDMIT), Université Paris-Saclay, Inserm, CEA, F- 92260 Fontenay-aux-Roses, France

17 <sup>4</sup>Institut Pasteur, Université Paris Cité, CNRS USR 3756, Biostatistics and Bioinformatics Hub, F-75015  
18 Paris, France

19 <sup>5</sup>Institut Pasteur, Université Paris Cité, CNRS UAR2024, Proteomic Platform, Mass Spectrometry for  
20 Biology Unit, F-75015 Paris, France

21 <sup>6</sup>Service de Bactériologie-Virologie, CHRU de Tours, F-37044 Tours, France

22 <sup>7</sup>Service de Médecine Interne et des Maladies Infectieuses, CHRU de Tours, F-37044 Tours, France

23 <sup>8</sup>Service d'Hémodialyse, CHRU de Tours, F-37044 Tours, France

24 <sup>9</sup>Service de Bactériologie-Hygiène, Centre Hospitalier Universitaire de Hôpital Bicêtre, Université Paris  
25 Saclay, AP-HP, Le Kremlin-Bicêtre, France

26 <sup>10</sup>Centre National de Référence Associé de la Résistance aux Antibiotiques, Le Kremlin-Bicêtre, France

27 <sup>11</sup>ISP, INRA, Université de Tours, UMR1282, F-37380 Nouzilly, France

28 <sup>¶</sup>Present address: Service de Médecine interne, CH Yves Le Foll, 22000 Saint Briec, France

29 <sup>#</sup>Authors contributed equally to this work

30

31 **\*Corresponding authors:**

32 Cyril Savin and Javier Pizarro-Cerdá

33 Unité de Recherche *Yersinia*

34 Institut Pasteur

35 28 rue du Dr Roux

36 75724 Paris Cedex 15, France

37 Phone: 00-33-1-40-61-37-67

38 e-mail: [cyril.savin@pasteur.fr](mailto:cyril.savin@pasteur.fr) ; [javier.pizarro-cerda@pasteur.fr](mailto:javier.pizarro-cerda@pasteur.fr)

39

40

## 41 **Abstract**

42           Following a pacemaker implantation, a 75-years-old patient suffered from five successive  
43 bacteremia episodes between in 1999 and 2013 despite long-term antibiotic treatment, with  
44 intermittent vegetation apparition on the device atrial lead. Four blood isolates, identified as *Yersinia*  
45 *enterocolitica* bioserotype 4/O:3, were further genetically and phenotypically characterized.  
46 Phylogenetic reconstruction showed that the patient was chronically infected by the same strain,  
47 which evolved within the host for 14 years. Single-nucleotide polymorphism (SNP) analysis indicates  
48 that the last two isolates evolved in parallel and formed two independent lineages within the host.  
49 Pan-genome analysis and genome comparison showed that their common evolution was  
50 characterized by 41 small insertion/deletion events, loss of three large DNA fragments and mutations  
51 in 140 genes. A phylogenetic analysis by maximum likelihood identified two genes presenting a  
52 positive selection signal, suggesting that these mutations provided a survival advantage to bacteria  
53 during chronic infection. Quinolone resistance in the last two isolates was acquired through a so far  
54 undescribed deletion in the *gyrA* gene.

55           Mass-spectrometry analysis revealed a strong proteome remodeling in the last two isolates  
56 which was correlated with a truncation in the stringent response regulator DksA. A reduced carbon,  
57 energy and purine metabolism supports their severe growth defects *in vitro*. 3<sup>rd</sup>-generation  
58 cephalosporin resistance of the last isolate was correlated with a truncation of OmpF, the main porin  
59 translocating antibiotics through the outer-membrane, as well as an increased production of BlaA  
60 and AmpC  $\beta$ -lactamases.

61           This is the first report of genetic and phenotypic changes associated to within-host  
62 adaptation of a pathogenic *Yersinia* species under antibiotic pressure.

63

64 **Keywords** : bacteremia/genomics/proteomics/within-host evolution/yersiniosis

## 65 Introduction

66 Bacterial exposure to a novel environment in a host creates conditions where evolution  
67 might take place. As observed for cancer cells, a bacterial clone can experience selection for an  
68 accumulation of genetic variants that promote long-term survival and clonal expansion<sup>1</sup>. This  
69 scenario has been observed in cystic fibrosis patients who can be chronically infected with  
70 pathogenic bacteria. In a study from a single patient infected for 20 years with *Burkholderia*  
71 *multivorans*, bacterial adaptation to respiratory airways was associated with mutations affecting  
72 metabolism, cell envelope, and biofilm formation<sup>2</sup>. In a different study concerning 474 *P. aeruginosa*  
73 isolates from 34 cystic fibrosis patients, convergent evolution of 52 genes involved in antibiotic  
74 resistance, motility, and biofilm formation was observed<sup>3</sup>. Host-adaptation through rapid evolution  
75 of a *Salmonella enterica* serotype Enteritidis causing a chronic systemic infection was documented in  
76 an immunocompromised patient<sup>4</sup>. Genetic diversification of *Staphylococcus epidermidis* has also  
77 been described during a 16-week pacemaker-associated endocarditis, leading to increased biofilm  
78 formation, reduced growth rate, and antibiotic tolerance<sup>5</sup>.

79 In-host evolution has not been reported for infections associated with *Yersinia* spp.  
80 Yersinioses include fulminant infections such as plague caused by *Yersinia pestis*, as well as mild or  
81 severe enteritis caused by *Yersinia pseudotuberculosis* or *Yersinia enterocolitica* (Ye)<sup>6,7</sup>. The latter  
82 represents the third most common cause of diarrhea from bacterial origin in temperate and cold  
83 countries<sup>8</sup>. Systemic Ye infections occur mostly in elderly patients with underlying disorders such as  
84 diabetes, iron overload, or cirrhosis<sup>9</sup>.

85 Persistent Ye infections in patients causing relapses for several years have been reported<sup>10</sup>,  
86 but the potential genetic relationships between the isolated strains was not determined. This study is  
87 the first report of long-term, in-host evolution of a pathogenic *Yersinia* species in a patient  
88 presenting iterative episodes of bacteremia over 14 years.

89

## 90 Results

### 91 Case description

92 A 75-year-old woman presented with an atrioventricular block that led to a pacemaker  
93 implantation in September 1998. In December 1999, the patient had a first septicemic episode  
94 resulting in the isolation of a Ye strain (Ye.1) (Fig 1). She received ceftriaxone and netilmicin  
95 treatment for 4 weeks and recovered. In January 2000, the patient experienced a second episode of  
96 bacteremia with isolation of another Ye strain (Ye.2). She was treated with the same antibiotics for  
97 four weeks, followed by 18 months of ciprofloxacin therapy (until July 2001), during which monthly

98 blood cultures were negative. A third bacteremia occurred in August 2001 with isolation of a third *Ye*  
99 (*Ye.X*, not kept in collection) that was resistant to nalidixic acid but susceptible to ciprofloxacin, which  
100 had been used for treatment. The patient received a long-term ceftriaxone therapy until July 2005,  
101 and monthly blood cultures were negative. In June 2006, the patient was hospitalized for a sepsis but  
102 had a negative blood culture. For the first time, echocardiography evidenced vegetations on the  
103 pacemaker atrial lead, suggesting endocarditis due to bacterial growth on the cardiac device (Fig S1).  
104 A 6-year ceftriaxone treatment was administered, leading to vegetation disappearance. In December  
105 2012, the patient suffered from pneumonia, and ceftriaxone treatment was replaced by spiramycin.  
106 In January 2013, she presented with another bacteremia with isolation of a fourth *Ye* strain (*Ye.3*)  
107 and vegetations reappeared on the pacemaker atrial lead. Strain *Ye.3*, like *Ye.X*, was resistant to  
108 nalidixic acid. The patient was treated with piperacillin/tazobactam/amikacin for one week, followed  
109 by a 9-month ceftriaxone therapy. The patient had a last bacteremia in October 2013, during which a  
110 fifth *Ye* strain (*Ye.4*) was isolated. Minimum inhibitory concentration (MIC) of ceftriaxone increased  
111 from 0.19 mg/L (*Ye.3*) to 2 mg/L (*Ye.4*) leading to antimicrobial treatment modification with  
112 cotrimoxazole. Three months later, the patient died of heart failure.

113

#### 114 **Phenotypic characterization of *Ye* isolates shows in-host evolution of antibiotic susceptibility** 115 **during long term treatment**

116 The five strains isolated during the iterative bacteremia were initially identified as *Ye* using a  
117 VITEK2 GN card. Except for *Ye.X*, which was not kept in collection, strains were subjected to  
118 phenotypical characterization: *Ye.1* and *Ye.2* (also referred as “early isolates”) were identified as *Ye*  
119 bioserotype 4/O:3; due to a severe growth defect, *Ye.3* and *Ye.4* (also referred as “late isolates”)   
120 could not be characterized by phenotypic methods. A substantial increase in mid-exponential phase  
121 doubling time at 37°C was measured, from 49 and 44 minutes for *Ye.1* and *Ye.2* to 5h38 and 4h46 for  
122 *Ye.3* and *Ye.4*, respectively. Doubling times at 28°C were slightly longer, with 57 minutes for *Ye.1* and  
123 *Ye.2*, 6h49 for *Ye.3* and 5h28 for *Ye.4* (Fig S2).

124 After isolation of the four strains, we parallelly assessed the susceptibility of *Ye.1* to *Ye.4* to  
125 33 different antibiotics or antibiotics combinations (Table S1). All strains were resistant to the  
126 penicillins amoxicillin and ticarcillin. *Ye.1* and *Ye.2* were resistant to first-generation cephalosporin  
127 (C1G) (data not shown) and they were susceptible to all other tested antibiotics, as usually observed  
128 for *Ye* bioserotype 4/O:3, although *Ye.2* showed a small resistance increase to several  $\beta$ -lactams and  
129 netilmicin, the aminoglycoside (AG) which was administered in combination with the 3<sup>rd</sup> generation  
130 cephalosporin (C3G) ceftriaxone between *Ye.1* and *Ye.2* isolation. *Ye.3* and *Ye.4* acquired a resistance

131 to the quinolone nalidixic acid, as observed with Ye.X, and Ye.4 became resistant to the second-  
132 generation cephalosporin (C2G) ceftiofur.

133 To further characterize the antibiotic profile of the isolated strains, the MIC of 10 antibiotics  
134 and antibiotics combinations was measured (Table 1). While the MIC of different antibiotics classes  
135 such as cephalosporin, AG and fluoroquinolone (FQ) slightly increased between Ye.1 and Ye.2, an  
136 unexpected AG and FQ MIC decrease was observed for the late isolates Ye.3 and Ye.4 compared to  
137 the early isolates Ye.1 and Ye.2. Furthermore, Ye.4 was fully resistant to the C3G ceftriaxone as well  
138 as the C2G ceftiofur, as observed before, and was slightly more resistant than Ye.3 to piperacillin-  
139 tazobactam, the combination of a penicillin and a  $\beta$ -lactamase inhibitor administered before  
140 ceftriaxone between Ye.3 and Ye.4 isolation.

141

### 142 **Genetic analysis supports a chronic *Ye* infection, unravels a new quinolone resistance mutation in** 143 ***gyrA* and reveals a OmpF-mediated cephalosporin resistance**

144 Taxonomic assignment of the 4 isolated strains was obtained based on a core-genome  
145 multilocus sequence typing (cgMLST) with 500 core genes using whole-genome *de novo* sequence,  
146 confirming that strains Ye.1 to Ye.4 belong to the *Ye* genotype 4, corresponding to bioserotype 4/O:3.

147 To investigate whether the multiple infection episodes were independent or due to a chronic  
148 colonization by a unique evolving bacterial strain, we studied the genetic relatedness of strains Ye.1  
149 to Ye.4 by a core-genome single-nucleotide polymorphism analysis, with inclusion of 259 additional  
150 *Ye* biotype 4 strains isolated between 1963 and 2016 (Table S2). The phylogenetic tree  
151 reconstruction based on analysis of 4,738 SNPs showed that Ye.1 to Ye.4 were closely related and  
152 formed a unique clade separated from other *Ye* strains (Fig 2A). This result strongly suggests that the  
153 patient suffered from a chronic infection due to a unique evolving *Ye* 4/O:3 strain.

154 We next analyzed the molecular events that characterized the in-host evolution of Ye.1 to  
155 Ye.4. Genomic comparison and pan-genome phylogenetic analysis did not evidence any gene  
156 acquisition or small insertion/deletion events that were common and specific to the four *Ye* isolates.  
157 Ye.1 (isolated in December 1999) and Ye.2 (isolated in January 2000) were identical except for the  
158 loss in Ye.1 of a 1.5 kb region (between nucleotides 4,282,424 and 4,283,952 from the Y11 reference  
159 genome), indicating that evolution had already started within the first months of infection. The use  
160 of the least-squares dating tool (<https://lsdating.pasteur.fr>) estimated the closest internal node for  
161 Ye.1 and Ye.2 in October 1999, suggesting that the patient was contaminated at least two months  
162 before the first bacteremic episode (Fig 2B). The closest internal node for Ye.3 (isolated in January  
163 2013) and Ye.4 (isolated in October 2013) was January 2011 (Fig 2B). However, a truncation in the  
164 mutation frequency decline *mfd* gene and the slow growth phenotype of the late isolates should be

165 considered, thus the divergence between Ye.3 and Ye.4 could have happened earlier. Their common  
166 ancestor had therefore evolved in the patient for at least 11 years and accumulated 285 SNPs before  
167 diverging into Ye.3 and Ye.4, which since accumulated additional 31 and 52 SNPs, respectively (Table  
168 S3). 140 genes containing mutations vertically acquired from their common ancestor  
169 (synapomorphies) were identified in the Ye.3 and Ye.4 genomes, including the *gyrA* gene (see below  
170 and Table S4). Ye.3 and Ye.4 shared three identical large deletions: a 2-gene deletion of 2.5 kb, a 9-  
171 gene deletion of 9.9 kb, and a 28-gene deletion of 32.7 kb (Table 2). These strains also shared 41  
172 small insertions/deletions (Table 2). Whereas 6 genes did not exhibit any frameshift, 35 genes  
173 displayed a mutation leading to a truncated form of the product, and thus to loss-of-function.  
174 Truncated genes and deleted regions were found to be involved in essential physiological functions  
175 such as transcription, translation, replication, respiration, division, and carbohydrate and iron  
176 metabolism (Table 2).

177 A positive selection signal was detected in all isolated strains, in the acyl-CoA thioesterase II,  
178 which regulates levels of acyl-CoAs, free fatty acids, and coenzyme A. In position 280 of this enzyme,  
179 a glycine is normally conserved in diverse eukaryotic and bacterial species<sup>11</sup> while in Ye.1 to Ye.4 a  
180 serine was present. Position 280 is located next to important residues involved in two catalytic triads  
181 (Q278 together with N204 and T228, as well as E279 together with H58 and S107) and a dimer  
182 interface (V277 and V281) and could possibly affect the catalytic and functional activities of the acyl-  
183 Coa thioesterase. Another positive selection signal was present in a phosphate transporter, for which  
184 the C-terminal region displayed a deletion observed only in Ye.3 and Ye.4 that affects two  
185 cytoplasmic and two transmembrane domains. While we did not investigate the specific contribution  
186 of this deletion to the functionality of the phosphate transporter, the positive selection signal  
187 suggests that the promoted changes provided a survival advantage (Table S5).

188 The genetic basis of antibiotic resistance was investigated upon bacterial genome  
189 sequencing. Comparison of *gyrA* sequences of Ye.1 to Ye.4 with those of the reference strain Y11 and  
190 strain IP38477, which are susceptible to nalidixic acid, showed that Ye.3 and Ye.4 displayed the same  
191 3-nucleotide deletion at positions 245 to 247 in the quinolone resistance-determining region (QRDR)  
192 of *gyrA* (Fig S3A). This so far undescribed deletion leads to replacement of aspartic acid 82 and serine  
193 83 with a unique glycine without any frameshift, explaining the genetic basis of the resistance to  
194 quinolones in Ye.3 and Ye.4 (Fig S3B). Additionally, a nucleotide substitution introduced a stop codon  
195 in position 78 of the Ye.4 *OmpF* porin, truncating the protein at one fifth of its length. Porin  
196 mutations are usually associated with a decreased antibiotics uptake through the outer-membrane  
197 and could explain cefoxitin and ceftriaxone resistance.



198 **Comparative proteomics of *Ye* isolates reveals an extensive metabolic rewiring, reduced virulence**  
199 **determinant expression and possibly OmpF-mediated antibiotics resistance**

200 To further characterize *Ye* evolution during the course of infection, we analyzed proteomes  
201 of the four isolates by mass spectrometry. We measured between 2,086 and 2,287 proteins in the 20  
202 samples (5 replicates of the 4 strains), for a total of 2,408 different proteins identified among all  
203 samples against a total database containing 4,424 unique proteins of the 4 isolates. All pairwise  
204 comparisons for protein differential abundance between strains were performed. 277 proteins were  
205 differentially abundant between the two early isolates *Ye*.1 and *Ye*.2 and 323 proteins between the  
206 two late isolates *Ye*.3 and *Ye*.4. In contrast, 845 to 1,070 proteins were differentially abundant in the  
207 4 pairwise comparisons of early versus late isolates, which account for almost half of the identified  
208 proteome (Dataset S1). These proteome differences correlate with the genetic distances of early and  
209 late isolates.

210 The annotated proteins from *Ye*.1 to *Ye*.4 were mapped to the *Ye* genotype 4 reference  
211 strain Y11 (Table S6). Gene set enrichment analysis (GSEA) on biological process gene ontology (GO)  
212 terms revealed isolate-specific variations as well as common trends in early versus late isolate  
213 comparisons (Fig 3). The loss of the pYV virulence plasmid (probably a laboratory artifact) in all  
214 strains but *Ye*.1 could be observed through the enrichment of the type III secretion system term in  
215 *Ye*.1. *Ye*.2 was specifically characterized by an enriched galactose metabolism. Translation and tRNA  
216 processing terms were strongly upregulated in late isolates and even more in *Ye*.4. Amino acid  
217 biosynthetic process was the most specific enriched term in late isolates versus early isolates.  
218 Mapping of the protein abundance comparisons on the global metabolic map of Y11 (Fig S4, S5) and  
219 on specific KEGG pathways (Fig S6) shows a strong metabolic rewiring from early to late isolates, such  
220 as a decreased purine, pyrimidine or riboflavin metabolism, one-carbon pool by folate, carbohydrate  
221 metabolism and oxidative phosphorylation, and a perturbed amino acid metabolism such as  
222 increased histidine, serine, tryptophan or leucine biosynthesis, or reduced arginine or methionine  
223 biosynthesis and glycine cleavage (Fig S6).

224 Virulence-associated proteins such as the attachment locus Ail, the fimbriae MyfA, the serine  
225 protease ecotin, superoxide dismutases or the positive regulator RovA were less abundant in late  
226 isolates, correlating with the increased abundance of the negative virulence regulators RovM or  
227 YmoA (Table 3). Additionally, a mutation in the initiation codon of the invasin *Inv* completely  
228 abrogated its production in *Ye*.4. On the other hand, the chemotactic operon *cheAWYZ* was more  
229 expressed in late isolates, along an increased expression of quorum sensing autoinducer-1 *yenI* and a  
230 decreased expression of autoinducer-2 operon *IsrGFBDcARK*. The invasin *Inv* was only slightly  
231 downregulated in *Ye*.3 but strongly in *Ye*.4 compared to early isolates.



232 Iron import systems such as the heme import system encoded by the *hmuRSTUV* operon or  
233 the TonB/ExbB/ExbD transport system were more abundant in the late isolates, while iron storage  
234 abundance such as the non-heme ferritin FtnA or the bacterioferritin Bfr was decreased. All these  
235 iron metabolism protein changes correlated with a decreased abundance of the iron metabolism  
236 repressor Fur, showing a probable adaptation to the iron-scarce environment during *Ye* evolution in  
237 the bloodstream.

238 We looked at the proteins level of resistance and susceptibility factors such as  $\beta$ -lactamase,  
239 porin or efflux pump. An upregulation of the category A  $\beta$ -lactamase BlaA was observed for the late  
240 strains, negatively correlating with the regulator AmpE. More importantly, the category C BlaB (or  
241 AmpC)  $\beta$ -lactamase was more abundant in the ceftriaxone-resistant isolate Ye.4 compared to all  
242 other isolates. In addition to its truncation in Ye.4, the porin OmpF was less abundant in Ye.2  
243 compared to Ye.1, probably causing a decreased permeability of the outer-membrane to antibiotics  
244 (Table 3). The OmpC porin showed variable abundance levels, correlating with OmpR/EnZ two  
245 components system abundance, while other porins such as OmpW and two other porins (Y11\_17651  
246 and Y11\_12201) were strongly upregulated in the late isolates.

247

#### 248 **Truncation of the stringent response regulator DksA is one of the main drivers of proteome** 249 **changes**

250 To better understand which genetic difference could be the cause of the overall changing  
251 proteome, the correlation of the 6 pairwise comparisons was assessed against 57 published *Ye*  
252 transcriptome comparisons (Table S7) that we previously gathered on the Yersiniomics database<sup>12</sup>.  
253 Interestingly, early vs late isolate comparisons had a correlation coefficient ranging from -0.29 to -  
254 0.43 with the comparisons of a *Ye* WT vs  $\Delta dksA$  mutant and was one of the most correlated  
255 experiments in our dataset (Table S8, Fig S7). These transcriptomes originated from a recent RNA-  
256 Sequencing study exploring the *Ye* stringent response on *Ye* bioserotype 1B/O:8 in WT,  $\Delta dksA$ ,  
257  $\Delta relA\Delta spoT$  and  $\Delta dksA\Delta relA\Delta spoT$  strains<sup>13</sup>. We considered the correlations with our proteomes as  
258 high considering the variation in the *Ye* genotype and culture conditions used, as well as the analytic  
259 differences between RNA-sequencing based transcriptomics and mass spectrometry-based  
260 proteomics. Strikingly, a truncation in *dksA* gene is also observed in our late isolates (Table 2), where  
261 only the 72 first amino acids (AA) out of 153 AA remains. This truncation could explain the  
262 differential abundance of ribosome-associated proteins such as the ribosome maturation factor  
263 RimM, ribosome hibernation promoting factor Hpf or ribosome-associated translation inhibitor RaiA,  
264 ultimately leading to ribosomal protein upregulation. tRNA-associated proteins were also more  
265 abundant in late isolates in a *dksA*-dependent way (Table S9). Other protein abundance changes

266 correlating with *dkcA* inactivation include the more abundant previously mentioned hemin  
267 transporter subunits HmuR, HmuS, HmuT, magnesium/cobalt transporter CorA, sulfurtransferase  
268 TusA, the shikimate and proline pathway enzyme AroB, AroK, ProA and ProB, DNA-binding  
269 transcriptional regulator Fis, two of the porins (Y11\_12201, Y11\_17651) or the acetate uptake  
270 transporter SatP among other. On the other hand, *dkcA* inactivation was associated to the  
271 downregulation of the previously mentioned *lsr* operon as well as the urease *ureABCDEFGD* and  
272 glycogen utilization *glgBXCAP* operons, of the ferritins FtnA and Bfr, stress response protein ElaB,  
273 superoxide dismutase SodC, entericidin A/B, glycine cleavage system enzyme GcvT or fatty acid  
274 degradation enzymes FadA and FadB (Table S9). Interestingly, *dkcA* deletion also correlated with a  
275 strong decrease in *acs* and *actP* genes, which were described as truncated in late isolates.  
276 Most importantly, the stationary phase sigma factor RpoS ( $\sigma^5$ ) expression was *dkcA*-dependent, and  
277 probably explain most of the regulated proteins such as ribosomal and metabolic enzymes.

278

## 279 Discussion

280 This is the first report of a chronic *Ye* infection case due to a strain evolving in the same  
281 patient. Between December 1999 and October 2013, antibiotics were apparently successful in the  
282 treatment of five independent *Ye* bacteremia episodes; however, discontinuation of antibiotics was  
283 always followed by a new bacteremia. The appearance of vegetations observed by echocardiography  
284 in 2006, and their disappearance during therapy, argue for *Ye* growth on the atrial lead of the  
285 pacemaker and release into the bloodstream during the antibiotic discontinuation periods.  
286 Genomic and proteomic analyses of four *Ye* strains (Ye.1 to Ye.4) isolated from the patient allowed us  
287 to identify different mechanisms to resist to various antibiotic classes. Resistance to nalidixic acid  
288 was already observed from August 2001 after long-term ciprofloxacin treatment. Resistance to  
289 quinolones usually involves mutations in the QRDR of the *gyrA* gene, leading either to (i) a change of  
290 glycine 81 into cysteine, (ii) a change of serine 83 into arginine, isoleucine, or cysteine, or (ii) a  
291 change of aspartic acid 87 into a tyrosine, asparagine, or glycine<sup>14-17</sup>. In Ye.3 and Ye.4, we observed a  
292 previously undescribed deletion of 3 nucleotides in the *gyrA* QRDR, leading to substitution of aspartic  
293 acid 82 and serine 83 by a unique glycine. Our work thus identifies a novel mutation in *gyrA* likely  
294 leading to quinolone resistance.  
295 After the long-term ciprofloxacin treatment was changed for the C3G ceftriaxone, Ye.4 became  
296 resistant to cefoxitin and ceftriaxone by abrogating OmpF porin production, a widely shared strategy  
297 to reduce membrane permeability to antibiotics<sup>18</sup> and shown to be induced in *Escherichia coli* upon  
298 exposure to ceftriaxone<sup>19</sup>. A previous work showing OmpF mutations (the highest molecular weight

299 called YOMP-C in this previous work) selected by cefoxitin treatment in *Ye* and leading to increased  
300  $\beta$ -lactam resistance supports the antibiotic import via this porin<sup>20</sup>.  $\beta$ -lactamase induction has long  
301 been studied in *Ye*<sup>21</sup> and a recent *in silico* study suggested an increased BlaB inducibility in *Ye* biotype  
302 4<sup>22</sup>. The class A  $\beta$ -lactamase BlaA and class C  $\beta$ -lactamase BlaB (or AmpC) were more abundant in the  
303 *Ye*.4 isolate, probably playing a synergistic role together with porin inactivation, as both  $\beta$ -lactamases  
304 have been shown to be involved in ceftriaxone resistance in *Ye* biotype 1B<sup>23</sup>. Moreover, the non-  
305 specific MIC increased for various antibiotics classes in *Ye*.2 could also be explained by a slightly  
306 reduced OmpF expression compared to *Ye*.1. Interestingly, the macrolide efflux pump MacA was  
307 more expressed in *Ye*.3, which was isolated during the pneumonia treatment with the macrolide  
308 spiramycin. However, no specific genetic event could be linked to all these proteome variations.

309 While no ciprofloxacin resistance was observed, *Ye*.X (which was isolated after ciprofloxacin  
310 treatment), *Ye*.3 and *Ye*.4 displayed a severe growth defect *in vitro*, which could account for  
311 increased antibiotics tolerance. Two major biological processes contribute indeed to antibiotic  
312 tolerance: biofilm formation<sup>24,25</sup> and slow growth and/or metabolic dormancy<sup>5,26,27</sup>. In the late  
313 isolates, we identified mutations in genes involved in metabolism or growth in several gene clusters.  
314 The cumulative mutations in genes encoding the RNA polymerase subunits RpoC<sup>28</sup> and RpoD, the  
315 pDNA topoisomerase ParE<sup>29</sup>, the 50S ribosomal protein RplF<sup>30,31</sup>, the rRNA methyltransferase  
316 RImE/RrmJ/FtsJ<sup>32,33</sup> or the stringent response regulator DksA<sup>34,35</sup> could account for slow growth.  
317 Proteomics analysis of the isolates revealed a strong metabolic rewiring with reduced carbohydrate  
318 utilization and reduced purine, pyrimidine and riboflavin folate metabolism, together with decreased  
319 respiration, which overall corroborate the slow growth phenotype.

320 Vegetations detected in the pacemaker argue for the formation of a biofilm by the *Ye* strains.  
321 *Ye* biofilm production has been reported on medical devices such as catheters or feeding tubes<sup>25,36</sup>.  
322 We identified several mutations in *Ye*.3 and *Ye*.4 which can be associated with loss of motility and  
323 planktonic growth, favoring biofilm formation: for example, mutation of the flagellar genes *flgD* in  
324 both *Ye*.3 and *Ye*.4, and *flgG* and *flgA* in *Ye*.4. Of note, loss-of-function mutations associated with  
325 decreased motility have been identified in *Burkholderia spp.* and *P. aeruginosa* isolates from cystic  
326 fibrosis patients<sup>2,3</sup>. In addition, flagellar assembly is repressed in adverse and nutrient-poor  
327 environments owing to its energetic cost<sup>37</sup>. In this direction, no flagellar proteins were detected for  
328 any isolate in our culture conditions, in agreement with the reported low flagellar expression in  
329 *Yersinia* species at 37°C<sup>38</sup>. Additionally, a decreased expression or inactivation of adherence and  
330 invasion factors to host cells such as Ail, MyfA or Inv could favor adhesion to an abiotic surface by  
331 other surface factors. However, proteomics observations regarding higher chemotaxis and quorum  
332 sensing AI-1 as well as lower quorum sensing AI-2 protein levels in late isolates prevent us to draw

333 definitive conclusions on biofilm formation capacities of these isolates. A recent study characterizing  
334 the *Ye* stringent response also showed reduced motility and biofilm formation in a  $\Delta dksA$  mutant,  
335 while a (p)ppGpp mutant  $\Delta relA\Delta spoT$  had an increased biofilm capability<sup>34</sup>, suggesting that our late  
336 isolates, truncated in DksA due to the third large deletion described in these isolates, had reduced  
337 abilities to form biofilms. However, these experiment from the literature were performed at 26°C  
338 and are not representative of bacterial *in vivo* behavior at 37°C.

339 Strikingly, late isolates seem more sensitive to various aminoglycosides and  
340 fluoroquinolones. DksA truncation could explain this phenotype, as a *dksA* mutation increased  
341 susceptibility to ciprofloxacin in *Y. pseudotuberculosis*<sup>35</sup> and to chloramphenicol and ampicillin in  
342 *Ye*<sup>34</sup>. However, this effect is species and condition specific as, in *Acinetobacter baumannii*, conflicting  
343 results have been reported concerning ciprofloxacin susceptibility<sup>39,40</sup>. Interestingly, a *dksA* mutation  
344 in *Pseudomonas aeruginosa* increased on the other hand survival when exposed to ciprofloxacin,  
345 strengthening the interest in studying bacterial tolerance in addition to resistance<sup>41</sup>. Finally, a *rlmE*  
346 (or *rrmJ/ftsJ*) mutation, found in the late isolates, also led to an increased susceptibility to  
347 chloramphenicol, gentamicin, spectinomycin and other antibiotics in *E. coli*<sup>32</sup>.

348 In addition to the evolutive pressure of antibiotics, *Ye* faced the host immune system,  
349 nutritional immunity as well as a specific environment requiring a metabolic switch to adapt to a new  
350 lifestyle in the blood<sup>42</sup>. Amino acid requirements such as tryptophan for survival in the blood could  
351 explain the perturbed amino acid biosynthesis pathways in the late isolates. Recent studies also  
352 highlighted the role of glycine and other amino acid in complement susceptibility, and metabolism  
353 adaptation could be a way to better survive the complement cascade<sup>43-45</sup>. Iron scarcity in the  
354 bloodstream favored the upregulation of iron transport and reduced abundance of iron storage  
355 proteins. Interestingly, these regulations were also observed in the transcriptome of the *dksA*  
356 mutant<sup>13</sup>.

357 DksA regulation of ribosome production, modulation of regulators such as RpoS or Fis or  
358 amino acid promoters is well documented in model bacteria<sup>46-51</sup> and was recently validated in *Ye* by  
359 transcriptomics<sup>13</sup>. We could observe these effects in the proteome of the late isolates lacking a  
360 functional DksA. DksA regulates the stringent response that the bacteria can experience during  
361 nutrient starvation, but is also linked to antibiotic exposure or immune stress<sup>52,53</sup>. The pppGpp  
362 pyrophosphatase GppA (or Ppx) was also mutated in the late isolates, probably reinforcing  
363 unbalanced (p)ppGpp levels and a dysregulated stringent response. As a substantial number of  
364 protein changes are associated with DksA truncation and that a strong phenotypic change is induced  
365 by *dksA* inactivation<sup>13,34,54</sup>, this mutation could have been specifically selected during in-host  
366 evolution, for example for the previously described iron transport. However, as the deletion has a

367 pleiotropic impact on the global transcriptome, it does not allow to distinguish a specific selection  
368 process from side-effects of the deletion. Moreover, it remains to be deciphered if the main selection  
369 pressure was the antibiotic treatment or the adaptation to the host environment, to temper a  
370 detrimental stringent response on the long run for example. Additionally, the Ye.4 isolate showed an  
371 even closer proteome to a  $\Delta dksA$  or  $\Delta relA\Delta spoT$  mutants than Ye.3, perceptible in the higher  
372 ribosomal content or decreased fatty acid degradation pathway for example, suggesting that  
373 ceftriaxone-resistant Ye.4 possess a more dysregulated stringent response which could be due  
374 to *OmpF* inactivation, reducing nutrient import. Alternatively, stringent response being an adaptation  
375 mechanism to a varying environment, its inactivation could have been simply selected by the  
376 evolution of the bacteria in a controlled and non-changing environment, the blood. This mechanism  
377 could synergistically happen along genome size reduction, a hallmark of environment specialization.

378 Interestingly, loss of the pore-forming toxin *YaxAB* (*Y11\_10331/Y11\_10321*) as well as  
379 reduced virulence factor abundance such as *Ail*, *MyfA*, superoxide dismutases, *ecotin*, *invasin* or the  
380 regulator *RovA* suggest that bacteria defective for pathogenic functions that carry a fitness cost can  
381 be selected to favor host adaptation, as argued for *Staphylococcus aureus*<sup>31,55,56</sup>. Finally, *Ye* late  
382 isolates displayed a mutation in *mfd*, previously showed to be required for diversification and  
383 antibiotics resistance<sup>57,58</sup>. This suggest that the late slow-growing isolates accumulated less  
384 mutations and evolved even slower than expected, while most of the in-host evolving strains  
385 previously described showed increased mutation rate<sup>59</sup>.

386

387 In conclusion, we report the unusual clinical case of a patient with iterative bacteremia and  
388 endocarditis due to a *Ye* bioserotype 4/O:3 strain evolving over a period of 14 years. The last two  
389 isolates, which were simultaneously evolving in the patient, accumulated mutations that allowed  
390 antibiotic resistance (a previously unknown substitution conferring resistance to quinolones) and  
391 possibly antibiotic tolerance. The latter phenotype was associated with a reduction in genome size  
392 and loss of essential functions for growth *in vitro*, while retaining the ability to survive in the host.  
393 The last isolated strains caused bacteremia despite the continuity of the antibiotic treatment,  
394 highlighting the transition occurring between early onset tolerance and resistance, a critical problem  
395 in antibiotic treatment that should urgently be addressed<sup>60-62</sup>. Our findings have implications in case  
396 management, as they reinforce the need for early pacemaker removal in addition to  
397 antibiotherapy<sup>63</sup>. They may also guide future design of more effective treatments for chronic and  
398 biofilm-associated bacterial infections. If the infected material cannot be removed as it was the case  
399 in our study, the choice of the right antibiotic is crucial. It must be well tolerated by the patient, be  
400 active on the biofilm and should not promote the emergence of resistance nor tolerance. It appears

401 here that long-term ceftriaxone has been well tolerated, however it induced tolerance and resistance  
402 to this antibiotic. Investigation of the mechanisms modulating antibiotic tolerance is therefore a  
403 critical issue for the treatment of long-term infections.

404

## 405 **Materials and Methods**

### 406 **Phenotypic characterization**

407 Bacterial strains were identified using the VITEK2 GN card (bioMérieux) and were sent to the *Yersinia*  
408 National Reference Laboratory (Institut Pasteur) for species confirmation/characterization as  
409 described<sup>64</sup>. For the growth curves, bacteria were precultured in 5 mL lysogeny broth (LB) at 37°C  
410 under agitation at 200 rotation per minute (rpm) for 16 to 96 hours. Precultures were diluted to  
411 OD<sub>600nm</sub>=0.1, and 2.5 mL were inoculated in 250 mL LB. Incubations were performed either at 28°C or  
412 37°C under agitation at 200 rpm. Optical density at 600 nm was recorded at different time points to  
413 monitor growth of the isolates. Mid-exponential phase growth rate was calculated between 2 and 4  
414 hours for Ye.1 and Ye.2, and between 7 and 31 hours for Ye.3 and Ye.4.

415

### 416 **Antibiotic resistance profiling**

417 The antibiotic resistance profiles of the bacterial strains were first determined using VITEK2  
418 (bioMérieux) and by disk diffusion method on Mueller-Hinton agar supplemented with 5% horse  
419 blood (bioMérieux) for growth deficient isolates during the course of the clinical case. A more  
420 comprehensive antibiotic resistance profiling and minimal inhibitory concentration (MIC)  
421 measurement was respectively performed by disk diffusion method and Etest on Mueller-Hinton  
422 agar supplemented with 5% horse blood (bioMérieux) for the four strains kept in collection at the  
423 end of the clinical case. Interpretation was performed according to the recommendations of the  
424 Antibiogram Committee of the French Society for Microbiology.

425

### 426 **Whole genome sequencing and analysis**

427 Bacterial genomes were sequenced and whole genome-based taxonomic assignment was obtained  
428 using a 500-gene cgMLST-*Yersinia* as previously described<sup>65</sup>.  
429 229 epidemiologically unrelated *Ye 4/O:3* strains isolated between 1982 and 2016 were also  
430 sequenced and public genomes of 34 additional strains were used for subsequent analysis (Table S2).  
431 Paired-end FASTQ files were used for variant calling using the Y11 reference strain (accession  
432 number: NC\_017564) with Snippy version 4.1.0<sup>66</sup>. Putative recombinogenic regions were detected  
433 and masked with Gubbins version 2.3.4<sup>67</sup>. A maximum-likelihood phylogenetic tree was built from an



434 alignment of 4,738 chromosomal SNPs with RAxML version 8.2.8<sup>68</sup>. Tree visualization was created  
435 with iTOL<sup>69</sup>.

436

#### 437 **Pan-genome phylogenetic analysis**

438 A total of 96 additional *Ye* strains were randomly selected together with the *Ye*.1-4 for Phylogenetic  
439 Analysis by Maximum Likelihood (PAML)<sup>70</sup>. A pan-genome was constructed using PPanGGOLiN<sup>71</sup>.  
440 Each gene of the pan-genome (3,824 genes) was translated to proteins and aligned using MAFFT  
441 v7.407<sup>72</sup>, allowing to search for genes specific to *Ye* isolates. Back translation to nucleotide was  
442 performed to obtain codon alignment, and a phylogenetic tree was built for each gene using IQ-TREE  
443 v1.6.7.2<sup>73</sup>. IQ-TREE's ModelFinder<sup>74</sup> was used to estimate the best variant of the General Time  
444 Reversible (GTR) model. The 3,612 genes for which the strains *Ye*.3 and *Ye*.4 are not sisters in the  
445 tree were removed. Synapomorphies were analyzed using a dedicated script  
446 (<https://gitlab.pasteur.fr/GIPhy/findSynapomorphies/>). PAML tests detected genes under positive  
447 selection pressure.

448

#### 449 **Proteomics sample preparation**

450 *Ye*.1 and *Ye*.2 strains were grown overnight in LB at 37°C under agitation at 200 rpm. 200 µL of the  
451 culture were plated on 5 tryptic soy agar (TSA) plates and incubated for 24 hours at 37°C. *Ye*.3 and  
452 *Ye*.4 were grown for 3 days in LB at 37°C under agitation at 200 rpm, then 200 µL of the culture were  
453 plated on 5 TSA plates and incubated for 48 hours at 37°C. For all *Ye* strains, the bacteria were  
454 resuspended with an inoculation loop from the TSA plates in 1 mL phosphate buffered saline (PBS)  
455 and washed two times by centrifugation and resuspension in PBS. Bacterial proteins were extracted  
456 as explained previously<sup>75</sup>. Briefly, bacteria were lysed with 20 µL trifluoroacetic acid (TFA) for 10  
457 minutes and transferred to a sterile 1.5 mL protein low-binding tube. 200 µL of 2M Tris were added,  
458 then 24 µL of 100mM tris(2-carboxyethyl)phosphine (TCEP), 400 mM chloroacetamide (CAA) for a  
459 final concentration of 10 mM TCEP and 40 mM CAA. Samples were incubated at 95°C for 5 minutes  
460 and proteins were quantified using tryptophan fluorescence in a Synergy H1M microplate reader  
461 (BioTek) with an excitation wavelength of 280 nm and an emission wavelength of 360 nm. 100 µg of  
462 proteins were aliquoted for each sample, and 5 volumes of water were added.  
463 Proteins were digested for 11 hours at 37°C under agitation at 600 rpm on a ThermoMix (Thermo)  
464 using Sequencing Grade Modified Trypsin (Promega - V5111) with a 1:50 ratio (enzyme:protein)  
465 before stopping the digestion by addition of TFA to reach a final pH lower than 2.  
466 20 µg of digested peptides were desalted using the Stage-Tips method<sup>76</sup> using C18 Empore disc,  
467 eluted with acetonitrile (ACN) 80%, formic acid (FA) 0.1%. Finally, the peptide solutions were speed-



468 vac dried and resuspended in ACN 2%, FA 0.1% buffer. For each sample, absorbance at 280 nm was  
469 measured with a Nanodrop™ 2000 spectrophotometer (Thermo Scientific) to inject an equivalent of  
470 DO = 1.  
471 For the spectral library preparation for data-independent analysis (DIA), 2 µg of each digested sample  
472 were pooled before proceeding to a peptide fractionation. The fractionation was performed with a  
473 poly(styrene-divinylbenzene) reverse phase sulfonate (SDB-RPS) Stage-Tips method as previously  
474 described<sup>76,77</sup>. 20µg of the pooled sample was loaded into 3 SDB-RPS (Empore™, 66886-U) discs  
475 stacked on a P200 tip and 8 serial elutions were applied as following: elution buffer 1 (Ammonium  
476 formate (AmF) 60 mM, ACN 20%, FA 0.5%), elution buffer 2 (AmF 80 mM, ACN 30%, FA 0.5%), elution  
477 buffer 3 (AmF 95 mM, ACN 40%, FA 0.5%) , elution buffer 4 (AmF 110 mM, ACN 50%, FA 0.5%),  
478 elution buffer 5 (AmF 130 mM, ACN 60%, FA 0.5%), elution buffer 6 (AmF 150 mM, ACN 70%, FA  
479 0.5%) and elution buffer 7 (ACN 80%, ammonium hydroxide 5%). All fractions were speed-vac dried  
480 and resuspended with ACN 2%, FA 0.1% before injection. For all fractions and individual samples, iRT  
481 peptides were spiked as recommended by Biognosys (Biognosys - Ki-3002-1).

482

#### 483 **LC-MS/MS proteomics**

484 For the creation of the spectral library, a nanochromatographic system (Proxeon EASY-nLC 1200 -  
485 Thermo Scientific) was coupled online with a Q Exactive™ HF mass spectrometer (Thermo Scientific).  
486 Peptides from each fraction and from the pooled sample were injected into a capillary column  
487 picotip silica emitter tip (home-made column, 39cm x 75 µm ID, 1.9 µm particles, 100 Å pore size,  
488 ReproSil-Pur Basic C18 - Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) after an equilibration  
489 step in 100 % mobile phase A (H<sub>2</sub>O, FA 0.1%). Peptides were eluted with a multi-step gradient from 2  
490 to 7% mobile phase B (ACN 80% / FA 0.1%) in 5 min, 7 to 23% B in 70 min, 23 to 45% B in 30 min and  
491 45 to 95% B in 5 min at a flow rate of 250 nL/min for up to 132 min. Column temperature was set to  
492 60°C. Mass spectra were acquired using Xcalibur software using a data-dependent Top 10 method  
493 with a survey scans (300-1700 m/z) at a resolution of 60,000 and MS/MS scans (fixed first mass 100  
494 m/z) at a resolution of 15,000. The AGC target and maximum injection time for the survey scans and  
495 the MS/MS scans were set to 3.0x10<sup>6</sup>, 100 ms and 1.0x10<sup>5</sup>, 45 ms respectively. The isolation window  
496 was set to 1.6 m/z and normalized collision energy fixed to 28 for HCD fragmentation. We used a  
497 minimum AGC target of 2.0x10<sup>3</sup> for an intensity threshold of 4.4x10<sup>4</sup>. Unassigned precursor ion  
498 charge states as well as 1, 7, 8 and >8 charged states were rejected and peptide match was disable.  
499 Exclude isotopes was enabled and selected ions were dynamically excluded for 30 seconds.  
500 For the DIA analysis, mass spectra were acquired in DIA mode with the same nanochromatographic  
501 system coupled on-line to a Q Exactive™ HF mass spectrometer. For each sample, 1 µg of peptides

502 was injected into the same capillary column picotip silica emitter tip after an equilibration step in 100  
503 % mobile phase A (H<sub>2</sub>O, FA 0.1%). Peptides were eluted using the same multi-step gradient and  
504 temperature for up to 125min. MS data was acquired using the Xcalibur software with a scan range  
505 from 295 to 1170 m/z. The DIA method consisted in a succession of one MS scan at a resolution of  
506 60,000 and 36 consecutive MS/MS scans with 1 Da overlapping windows (isolation window = 25 m/z)  
507 at 30,000 resolution. The AGC (Automatic Gain Control) target and maximum injection time for MS  
508 and MS/MS scans were set to  $3.0 \times 10^6$ , 60 ms and  $2.0 \times 10^5$ , auto respectively. The normalized collision  
509 energy was set to 28 for HCD fragmentation.

510

### 511 **Proteome bioinformatic analysis**

512 MaxQuant analyses: DDA raw files were processed using MaxQuant software version 1.6.6.0<sup>78</sup> with  
513 Andromeda search engine<sup>79</sup>. The MS/MS spectra were searched against a personal *Yersinia*  
514 *enterocolitica* database (4,424 entries). The database was created by combining the four different  
515 *Yersinia enterocolitica* strains (Ye.1, Ye.2, Ye.3 and Ye.4). Sequences with at least one different amino  
516 acid were considered as unique and specific of the corresponding strain. Sequences with 100%  
517 similarity were reported once. FASTA headers contain the traceability of each strain.

518 Variable modifications (methionine oxidation and N-terminal acetylation) and fixed modification  
519 (cysteine carbamidomethylation) were set for the search and trypsin with a maximum of two missed  
520 cleavages was chosen. The minimum peptide length was set to 7 amino acids and the false discovery  
521 rate (FDR) for peptide and protein identification was set to 0.01. The main search peptide tolerance  
522 was set to 4.5 ppm and to 20 ppm for the MS/MS match tolerance. Second peptides were enabled to  
523 identify co-fragmentation events.

524 Spectronaut analyses: Spectronaut v. 16.0.220606 (Biognosys AG)<sup>80</sup> was used for DIA-MS data  
525 analyses. Data extraction was performed using the default BGS Factory Settings. Briefly, for  
526 identification, both precursor and protein FDR were controlled at 1%. For quantification, Qvalue was  
527 used for precursor filtering and global imputation strategy was used; peptides were grouped based  
528 on stripped sequences. Cross Run Normalization was enabled.

529

### 530 **Proteome statistical analysis**

531 To find the proteins more abundant in one condition than in another, the intensities quantified using  
532 Spectronaut were compared. Only proteins identified with at least one peptide and with at least four  
533 intensity values in one of the two compared conditions were kept for further statistics. First, proteins  
534 absent in a condition and present in another are put aside. These proteins can directly be assumed  
535 differentially abundant between the conditions. Then, intensities of the remaining proteins were first

536 log-transformed ( $\log_2$ ). Intensity values were normalized by median centering within conditions  
537 (section 3.5 in this reference<sup>81</sup>). Missing values were imputed using the `impute.slsa` function of the R  
538 package `imp4p`<sup>82</sup>. Statistical testing was conducted using a `limma` t-test thanks to the R package  
539 `limma`<sup>83</sup>. An adaptive Benjamini-Hochberg procedure was applied on the resulting p-values thanks to  
540 the function `adjust.p` of the `cp4p` R package<sup>84</sup> using the robust method described in this reference<sup>85</sup>  
541 to estimate the proportion of true null hypotheses among the set of statistical tests. The proteins  
542 associated to an adjusted p-value inferior to a FDR level of 1% and an absolute  $\log_2$ (fold-change)  
543 superior to 1 have been considered as significant and differentially abundant proteins. Finally, the  
544 proteins of interest are therefore those which emerge from this statistical analysis supplemented by  
545 those which are present from one condition and absent in another (“ID table” in the S1 Dataset).  
546 Annotated proteins of Ye.1 to Ye.4 strains were blasted on the Y11 reference proteome (RefSeq  
547 annotation from December 2022, accession GCF\_000253175.1), and the best hit for each Y11 protein  
548 was kept. For each pairwise comparison based on the Ye.1 to Ye.4 loci database describe above, the  
549 duplicated Y11 loci were removed by keeping the less differentially expressed value, assuming the  
550 duplicated loci came from an annotation of a protein carrying a SNP. The R package `clusterProfiler`  
551 v4.6.2 was used for enrichment and gene set enrichment analysis<sup>86</sup>. The GSEA function was used  
552 based on the Y11 loci by mapping to an in-house annotation file extracted from the Y11 Gene  
553 Ontology terms downloaded from the QuickGo website accessed on May 25<sup>th</sup> 2023<sup>87</sup>. The `gseKEGG`  
554 function was used with the online KEGG dataset for the “yey” organism accessed on May 25<sup>th</sup> 2023.  
555 Analysis was performed with the detected proteins as statistical background. Foldchange data were  
556 transformed to be uploaded on the iPath3 website<sup>88</sup>. Foldchange data were also mapped to specific  
557 KEGG pathways using the R package `pathview`<sup>89</sup>. Published transcriptomes were downloaded from  
558 the Yersiniomics website<sup>12</sup>. Ye 8081, Y1 and Y11 reference genomes were blasted to find  
559 homologous loci, and proteomes and transcriptomes were fused in a unique dataframe. The  
560 `rquery.cormat` function was used to compute the Pearson correlations of the foldchanges and display  
561 the correlation matrix.

562

## 563 **Data Availability Section**

564 The datasets and computer code produced in this study are available in the following databases:

- 565 • Genome sequences: ENA PRJEB19854 (sample ID starting with ERS and accession numbers  
566 starting with FWC) for *Y. enterocolitica* 1 (Ye.1) (ERS1580350, FWCF02000001-  
567 FWCF02000181), Ye.2 (ERS1580351, FWCE02000001-FWCE02000227), Ye.3 (ERS1580352,  
568 FWCB02000001-FWCB02000195), and Ye.4 (ERS1580353, FWCD02000001-FWCD02000173)

- 569       • The mass spectrometry proteomics data have been deposited to the ProteomeXchange  
570           Consortium via the PRIDE partner repository<sup>90</sup> with the dataset identifier PXD043567

571

## 572 **Acknowledgements**

573 This work was funded by Santé Publique France (SpF, Saint-Maurice, France), Institut Pasteur,  
574 Direction Générale de l'Armement, Agence Innovation Défense, Fondation pour la Recherche  
575 Médicale (FDT20220401-711 5222), the Inception program (Investissement d'Avenir grant ANR-16-  
576 CONV-0005), ANRS Emerging Infectious Disease (ANRS0349b) and Université Paris Cité. The *Yersinia*  
577 Research Unit is a member of the LabEX IBEID (ANR-10LBX-62-IBEID). We thank Vincent Enouf and  
578 Andreea Alexandru (P2M platform, Institut Pasteur, Paris, France) for the sequencing of the strains,  
579 Daniel Boury (SID'COM, University of Tours) for transesophageal echocardiography image processing,  
580 and Pr. Frédéric Patat (University Hospital of Tours) for transesophageal echocardiography image  
581 interpretation.

582 Some figures were created with BioRender.

## 583 **Conflict of interest**

584 The authors declare no competing interests.

## 585 References

- 586 1. Didelot, X., Walker, A. S., Peto, T. E., Crook, D. W. & Wilson, D. J. Within-host evolution of  
587 bacterial pathogens. *Nat Rev Microbiol* **14**, 150–162 (2016).
- 588 2. Silva, I. N. *et al.* Long-term evolution of *Burkholderia multivorans* during a chronic cystic  
589 fibrosis infection reveals shifting forces of selection. *mSystems* **1**, (2016).
- 590 3. Marvig, R. L., Sommer, L. M., Molin, S. & Johansen, H. K. Convergent evolution and adaptation  
591 of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nat Genet* **47**, 57–64 (2015).
- 592 4. Klemm, E. J. *et al.* Emergence of host-adapted *Salmonella* Enteritidis through rapid evolution  
593 in an immunocompromised host. *Nat Microbiol* **1**, 15023 (2016).
- 594 5. Dengler Haunreiter, V. *et al.* In-host evolution of *Staphylococcus epidermidis* in a pacemaker-  
595 associated endocarditis resulting in increased antibiotic tolerance. *Nat Commun* **10**, 1149  
596 (2019).
- 597 6. Carniel, E. *et al.* *Y. enterocolitica* and *Y. pseudotuberculosis*. in *The Prokaryotes* (ed. Springer)  
598 vol. 6 270–398 (Dworkin, New York, 2006).
- 599 7. Perry, R. D. & Fetherston, J. D. *Yersinia pestis*--etiologic agent of plague. *Clin Microbiol Rev* **10**,  
600 35–66 (1997).
- 601 8. The European Union One Health 2022 Zoonoses Report. *EFSA Journal* **21**, (2023).
- 602 9. Bottone, E. J. *Yersinia enterocolitica*: the charisma continues. *Clin Microbiol Rev* **10**, 257–276  
603 (1997).
- 604 10. Hoogkamp-Korstanje, J. A. A., de Koning, J. & Heesemann, J. Persistence of *Yersinia*  
605 *enterocolitica* in man. *Infection* **16**, 81–85 (1988).
- 606 11. Li, J., Derewenda, U., Dauter, Z., Smith, S. & Derewenda, Z. S. Crystal structure of the  
607 *Escherichia coli* thioesterase II, a homolog of the human Nef binding enzyme. *Nat Struct Biol* **7**,  
608 555–559 (2000).
- 609 12. Lê-Bury, P. *et al.* Yersiniomics, a multi-omics interactive database for *Yersinia* species.  
610 *Microbiol Spectr* **11**, e0382622 (2023).
- 611 13. Huang, C., Li, W. & Chen, J. Transcriptomic analysis reveals key Roles of (p)ppGpp and DksA in  
612 regulating metabolism and chemotaxis in *Yersinia enterocolitica*. *Int J Mol Sci* **24**, 7612 (2023).
- 613 14. Capilla, S. *et al.* Characterization of the molecular mechanisms of quinolone resistance in  
614 *Yersinia enterocolitica* O:3 clinical isolates. *J Antimicrob Chemother* **53**, 1068–1071 (2004).
- 615 15. Drummond, N., Stephan, R., Haughton, P., Murphy, B. P. & Fanning, S. Further  
616 characterization of three *Yersinia enterocolitica* strains with a nalidixic acid-resistant  
617 phenotype isolated from humans with diarrhea. *Foodborne Pathog Dis* **10**, 744–746 (2013).

- 618 16. Sanchez-Cespedes, J. *et al.* Clonal dissemination of *Yersinia enterocolitica* strains with various  
619 susceptibilities to nalidixic acid. *J Clin Microbiol* **41**, 1769–1771 (2003).
- 620 17. Sihvonen, L. M. *et al.* Multilocus variable-number tandem-repeat analysis, pulsed-field gel  
621 electrophoresis, and antimicrobial susceptibility patterns in discrimination of sporadic and  
622 outbreak-related strains of *Yersinia enterocolitica*. *BMC Microbiol* **11**, 42 (2011).
- 623 18. Prajapati, J. D., Kleinekathöfer, U. & Winterhalter, M. How to enter a bacterium: bacterial  
624 porins and the permeation of antibiotics. *Chem Rev* **121**, 5158–5192 (2021).
- 625 19. Ching, C. & Zaman, M. H. Identification of multiple low-level resistance determinants and  
626 coselection of motility impairment upon sub-MIC ceftriaxone exposure in *Escherichia coli*.  
627 *mSphere* **6**, (2021).
- 628 20. Brzostek, K. & Hrebenda, J. Outer-membrane permeability to  $\beta$ -lactam antibiotics in *Yersinia*  
629 *enterocolitica*. *J Gen Microbiol* **134**, 1535–1540 (1988).
- 630 21. Pham, J. N., Bell, S. M., Martin, L. & Carniel, E. The beta-lactamases and beta-lactam antibiotic  
631 susceptibility of *Yersinia enterocolitica*. *J Antimicrob Chemother* **46**, 951–957 (2000).
- 632 22. Singhal, N., Pandey, D., Singh, N. S., Kumar, M. & Viridi, J. S. Exploring the genetic  
633 determinants underlying the differential production of an inducible chromosomal  
634 cephalosporinase - BlaB in *Yersinia enterocolitica* biotypes 1A, 1B, 2 and 4. *Scientific Reports*  
635 *2020 10:1* **10**, 1–8 (2020).
- 636 23. Bent, Z. W. & Young, G. M. Contribution of BlaA and BlaB  $\beta$ -lactamases to antibiotic  
637 susceptibility of *Yersinia enterocolitica* biovar 1B. *Antimicrob Agents Chemother* **54**, 4000  
638 (2010).
- 639 24. Girard, L. P., Ceri, H., Gibb, A. P., Olson, M. & Sepandj, F. MIC versus MBEC to determine the  
640 antibiotic sensitivity of *Staphylococcus aureus* in peritoneal dialysis peritonitis. *Perit Dial Int*  
641 **30**, 652–656 (2010).
- 642 25. Ioannidis, A., Kyratsa, A., Ioannidou, V., Bersimis, S. & Chatzipanagiotou, S. Detection of  
643 biofilm production of *Yersinia enterocolitica* strains isolated from infected children and  
644 comparative antimicrobial susceptibility of biofilm versus planktonic forms. *Mol. Diag. Ther.*  
645 **18**, 309–314 (2014).
- 646 26. Brauner, A., Fridman, O., Gefen, O. & Balaban, N. Q. Distinguishing between resistance,  
647 tolerance and persistence to antibiotic treatment. *Nat Rev Microbiol* **14**, 320–330 (2016).
- 648 27. Fridman, O., Goldberg, A., Ronin, I., Shores, N. & Balaban, N. Q. Optimization of lag time  
649 underlies antibiotic tolerance in evolved bacterial populations. *Nature* **513**, 418–421 (2014).
- 650 28. Nandy, P., Chib, S. & Seshasayee, A. A mutant RNA polymerase activates the general stress  
651 response, enabling *Escherichia coli* adaptation to late prolonged stationary phase. *mSphere* **5**,  
652 (2020).

- 653 29. Harms, A. *et al.* Adenylation of gyrase and topo IV by FicT toxins disrupts bacterial DNA  
654 topology. *Cell Rep* **12**, 1497–1507 (2015).
- 655 30. Norstrom, T., Lannergard, J. & Hughes, D. Genetic and phenotypic identification of fusidic  
656 acid-resistant mutants with the small-colony-variant phenotype in *Staphylococcus aureus*.  
657 *Antimicrob Agents Chemother* **51**, 4438–4446 (2007).
- 658 31. Proctor, R. A. *et al.* *Staphylococcus aureus* small colony variants (SCVs): a road map for the  
659 metabolic pathways involved in persistent infections. *Front Cell Infect Microbiol* **4**, 99 (2014).
- 660 32. Caldas, T., Binet, E., Bouloc, P. & Richarme, G. Translational defects of *Escherichia coli* mutants  
661 deficient in the Um2552 23S ribosomal RNA methyltransferase RrmJ/FtsJ. *Biochem Biophys*  
662 *Res Commun* **271**, 714–718 (2000).
- 663 33. Pletnev, P. *et al.* Comprehensive Functional Analysis of Escherichia coli Ribosomal RNA  
664 Methyltransferases. *Front Genet* **11**, 472170 (2020).
- 665 34. Huang, C., Meng, J., Li, W. & Chen, J. Similar and divergent roles of stringent regulator  
666 (p)ppGpp and DksA on pleiotropic phenotype of *Yersinia enterocolitica*. *Microbiol Spectr* **10**,  
667 (2022).
- 668 35. Willcocks, S. *et al.* Genome-wide assessment of antimicrobial tolerance in *Yersinia*  
669 *pseudotuberculosis* under ciprofloxacin stress. *Microb Genom* **5**, e000304 (2019).
- 670 36. Hurrell, E. *et al.* Neonatal enteral feeding tubes as loci for colonisation by members of the  
671 *Enterobacteriaceae*. *BMC Infect Dis* **9**, 146 (2009).
- 672 37. Zhao, K., Liu, M. & Burgess, R. R. Adaptation in bacterial flagellar and motility systems: from  
673 regulon members to 'foraging'-like behavior in *E. coli*. *Nucleic Acids Res* **35**, 4441–4452 (2007).
- 674 38. Horne, S. M. & Prüß, B. M. Global gene regulation in *Yersinia enterocolitica*: effect of FliA on  
675 the expression levels of flagellar and plasmid-encoded virulence genes. *Arch Microbiol* **185**,  
676 115–126 (2006).
- 677 39. Maharjan, R. P. *et al.* DksA is a conserved master regulator of stress response in *Acinetobacter*  
678 *baumannii*. *Nucleic Acids Res* **51**, 6101–6119 (2023).
- 679 40. Kim, N. *et al.* Dksa modulates antimicrobial susceptibility of *Acinetobacter baumannii*.  
680 *Antibiotics* **10**, 1472 (2021).
- 681 41. Viducic, D. *et al.* Functional analysis of *spoT*, *relA* and *dksA* genes on quinolone tolerance in  
682 *Pseudomonas aeruginosa* under nongrowing condition. *Microbiol Immunol* **50**, 349–357  
683 (2006).
- 684 42. Lê-Bury, P., Echenique-Rivera, H., Pizarro-Cerdá, J. & Dussurget, O. Determinants of bacterial  
685 survival and proliferation in blood. *FEMS Microbiol Rev* (2024) doi:10.1093/FEMSRE/FUAE013.
- 686 43. Cheng, Z. xue *et al.* Glycine, serine and threonine metabolism confounds efficacy of  
687 complement-mediated killing. *Nature Communications* 2019 10:1 **10**, 1–17 (2019).



- 688 44. Kou, T. shun *et al.* Exogenous glycine promotes oxidation of glutathione and restores  
689 sensitivity of bacterial pathogens to serum-induced cell death. *Redox Biol* **58**, 102512 (2022).
- 690 45. Kou, T. shun *et al.* Exogenous glycine promotes oxidation of glutathione and restores  
691 sensitivity of bacterial pathogens to serum-induced cell death. *Redox Biol* **58**, 102512 (2022).
- 692 46. Mallik, P., Paul, B. J., Rutherford, S. T., Gourse, R. L. & Osuna, R. DksA is required for growth  
693 phase-dependent regulation, growth Rate-dependent control, and stringent control of *fis*  
694 expression in *Escherichia coli*. *J Bacteriol* **188**, 5775 (2006).
- 695 47. Lemke, J. J. *et al.* Direct regulation of *Escherichia coli* ribosomal protein promoters by the  
696 transcription factors ppGpp and DksA. *Proc Natl Acad Sci U S A* **108**, 5712–5717 (2011).
- 697 48. Brown, L., Gentry, D., Elliott, T. & Cashel, M. DksA affects ppGpp induction of RpoS at a  
698 translational level. *J Bacteriol* **184**, 4455–4465 (2002).
- 699 49. Boyle, W. K. *et al.* DksA-dependent regulation of RpoS contributes to *Borrelia burgdorferi* tick-  
700 borne transmission and mammalian infectivity. *PLoS Pathog* **17**, e1009072 (2021).
- 701 50. Paul, B. J., Berkmen, M. B. & Gourse, R. L. DksA potentiates direct activation of amino acid  
702 promoters by ppGpp. *Proc Natl Acad Sci U S A* **102**, 7823–7828 (2005).
- 703 51. Gourse, R. L. *et al.* Transcriptional responses to ppGpp and DksA.  
704 <https://doi.org/10.1146/annurev-micro-090817-062444> **72**, 163–184 (2018).
- 705 52. Qi, W. *et al.* The effect of the stringent response and oxidative stress response on fitness costs  
706 of *de novo* acquisition of antibiotic resistance. *International Journal of Molecular Sciences*  
707 *2024, Vol. 25, Page 2582* **25**, 2582 (2024).
- 708 53. Chau, N. Y. E., Ahmad, S., Whitney, J. C. & Coombes, B. K. Emerging and divergent roles of  
709 pyrophosphorylated nucleotides in bacterial physiology and pathogenesis. *PLoS Pathog* **17**,  
710 e1009532 (2021).
- 711 54. Huang, C., Li, W. & Chen, J. Stringent response factor DksA contributes to fatty acid  
712 degradation function to influence cell membrane stability and polymyxin B resistance of  
713 *Yersinia enterocolitica*. *Int J Mol Sci* **24**, 11951 (2023).
- 714 55. Das, S. *et al.* Natural mutations in a *Staphylococcus aureus* virulence regulator attenuate  
715 cytotoxicity but permit bacteremia and abscess formation. *Proc Natl Acad Sci U S A* **113**,  
716 E3101–E3110 (2016).
- 717 56. Ding, X. *et al.* Airway environment drives the selection of quorum sensing mutants and  
718 promote *Staphylococcus aureus* chronic lifestyle. *Nature Communications* *2023 14:1* **14**, 1–13  
719 (2023).
- 720 57. Han, J., Sahin, O., Barton, Y. W. & Zhang, Q. Key role of Mfd in the development of  
721 fluoroquinolone resistance in *Campylobacter jejuni*. *PLoS Pathog* **4**, e1000083 (2008).

- 722 58. Ragheb, M. N. *et al.* Inhibiting the evolution of antibiotic resistance. *Mol Cell* **73**, 157-165.e5  
723 (2019).
- 724 59. Dekker, J. P. Within-host evolution of bacterial pathogens in acute and chronic infection.  
725 <https://doi.org/10.1146/annurev-pathmechdis-051122-111408> **19**, (2023).
- 726 60. Levin-Reisman, I., Brauner, A., Ronin, I. & Balaban, N. Q. Epistasis between antibiotic  
727 tolerance, persistence, and resistance mutations. *Proc Natl Acad Sci U S A* **116**, 14734–14739  
728 (2019).
- 729 61. Levin-Reisman, I. *et al.* Antibiotic tolerance facilitates the evolution of resistance. *Science*  
730 (1979) **355**, 826–830 (2017).
- 731 62. Windels, E. M. *et al.* Bacterial persistence promotes the evolution of antibiotic resistance by  
732 increasing survival and mutation rates. *ISME J* **13**, 1239–1251 (2019).
- 733 63. De Silva, K., Fife, A., Murgatroyd, F. & Gall, N. Pacemaker endocarditis: an important clinical  
734 entity. *BMJ Case Rep* **2009**, (2009).
- 735 64. Le Guern, A. S., Martin, L., Savin, C. & Carniel, E. Yersiniosis in France: overview and potential  
736 sources of infection. *Int J Infect Dis* **46**, 1–7 (2016).
- 737 65. Savin, C. *et al.* Genus-wide *Yersinia* core-genome multilocus sequence typing for species  
738 identification and strain characterization. *Microb Genom* **5**, (2019).
- 739 66. Seemann, T. Snippy: rapid haploid variant calling and core genome alignment.  
740 <https://github.com/tseemann/snippy> (2015).
- 741 67. Croucher, N. J. *et al.* Rapid phylogenetic analysis of large samples of recombinant bacterial  
742 whole genome sequences using Gubbins. *Nucleic Acids Res* **43**, e15 (2015).
- 743 68. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large  
744 phylogenies. *Bioinformatics* **30**, 1312–1313 (2014).
- 745 69. Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments.  
746 *Nucleic Acids Res* (2019) doi:10.1093/nar/gkz239.
- 747 70. Yang, Z. PAML 4: phylogenetic analysis by maximum likelihood. *Mol Biol Evol* **24**, 1586–1591  
748 (2007).
- 749 71. Gautreau, G. *et al.* PPanGGOLiN: depicting microbial diversity via a partitioned pangenome  
750 graph. *PLoS Comput Biol* **16**, e1007732 (2020).
- 751 72. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:  
752 improvements in performance and usability. *Mol Biol Evol* **30**, 772–780 (2013).
- 753 73. Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective  
754 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* **32**, 268–  
755 274 (2015).

- 756 74. Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermini, L. S.  
757 ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat Methods* **14**, 587–  
758 589 (2017).
- 759 75. Lê-Bury, P. *et al.* Dual proteomic signature of immune cells and *Yersinia pestis* upon blood  
760 infection. *bioRxiv* 2023.06.19.545537 (2023) doi:10.1101/2023.06.19.545537.
- 761 76. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-  
762 fractionation and storage of peptides for proteomics using StageTips. *Nat Protoc* **2**, 1896–  
763 1906 (2007).
- 764 77. Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated proteomic-  
765 sample processing applied to copy-number estimation in eukaryotic cells. *Nat Methods* **11**,  
766 319–324 (2014).
- 767 78. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-  
768 range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* **26**, 1367–  
769 1372 (2008).
- 770 79. Cox, J. *et al.* Andromeda: a peptide search engine integrated into the MaxQuant environment.  
771 *J Proteome Res* **10**, 1794–1805 (2011).
- 772 80. Bruderer, R. *et al.* Extending the limits of quantitative proteome profiling with data-  
773 independent acquisition and application to acetaminophen-treated three-dimensional liver  
774 microtissues. *Molecular & Cellular Proteomics* **14**, 1400–1410 (2015).
- 775 81. Gai Gianetto, Q. Statistical analysis of post-translational modifications quantified by label-free  
776 proteomics across multiple biological conditions with R: illustration from SARS-CoV-2 infected  
777 cells. *Methods in Molecular Biology* **2426**, 267–302 (2023).
- 778 82. Gai Gianetto, Q., Wieczorek, S., Couté, Y. & Burger, T. A peptide-level multiple imputation  
779 strategy accounting for the different natures of missing values in proteomics data. *bioRxiv*  
780 2020.05.29.122770 (2020) doi:10.1101/2020.05.29.122770.
- 781 83. Ritchie, M. E. *et al.* *limma* powers differential expression analyses for RNA-sequencing and  
782 microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
- 783 84. Gai Gianetto, Q. *et al.* Calibration plot for proteomics: a graphical tool to visually check the  
784 assumptions underlying FDR control in quantitative experiments. *Proteomics* **16**, 29–32  
785 (2016).
- 786 85. Pounds, S. & Cheng, C. Robust estimation of the false discovery rate. *Bioinformatics* **22**, 1979–  
787 1987 (2006).
- 788 86. Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *The*  
789 *Innovation* **2**, 100141 (2021).


- 790 87. Binns, D. *et al.* QuickGO: a web-based tool for Gene Ontology searching. *Bioinformatics* **25**,  
791 3045 (2009).
- 792 88. Darzi, Y., Letunic, I., Bork, P. & Yamada, T. iPath3.0: interactive pathways explorer v3. *Nucleic*  
793 *Acids Res* **46**, W510–W513 (2018).
- 794 89. Luo, W. & Brouwer, C. Pathview: an R/Bioconductor package for pathway-based data  
795 integration and visualization. *Bioinformatics* **29**, 1830–1831 (2013).
- 796 90. Perez-Riverol, Y. *et al.* The PRIDE database resources in 2022: a hub for mass  
797 spectrometry-based proteomics evidences. *Nucleic Acids Res* **50**, D543–D552 (2022).
- 798

799

800 **AUTHOR CONTRIBUTIONS**


801 C.S. and P.L.-B. planned, performed and analyzed experiments with the help of L.M., N.C. and L.G.  
802 J.G. set up and performed pan-genome together with PAML analysis. R.B., C.L.-B., F.B., M.F. and B.M.  
803 are the physicians who took care of the patient and shared all the clinico-epidemiological data. L.D.  
804 performed antibiograms and MIC measurement. T.D. performed mass spectrometry-based  
805 proteomics. P.L.-B. and O.D. were involved in proteome analysis and identification of antibiotic  
806 tolerance mechanism. C.S., P.L.-B. and J.P.-C. interpreted data and wrote the manuscript. E.C., O.D.,  
807 M. M., P.L. and J.P.-C. supervised the work. C.S. and P.L.-B. are shared first authors and P.L. and J.P.-  
808 C. are shared last authors.  
809

810 **Figures**




811 **Figure 1.** Clinical case description of Ye chronic infection. Positive and negative symbols reflect the blood culture results, or the observation of vegetations  
 812 on the pacemaker atrial lead. Periods of antibiotics treatment are shown in a darker color on the chronograph, with the associated treatment names on the  
 813 left and antibiotic classes on the right. Abx: antibiotics. CeftriaxoneR: resistant to ceftriaxone. Nalidixic acidR: resistant to nalidixic acid. Sulf: sulfonamide.  
 814 DHFR inh: dihydrofolate reductase inhibitor.

815



816 **Figure 2.** Phylogenetic reconstruction. (A) Maximum likelihood phylogeny reconstructed with RAXML  
817 under GTR model with 100 bootstraps based on 4,738 SNPs identified in 262 strains. The genome of  
818 the Y11 strain (NC\_017564) was used as reference for variant calling. Numbers close to the branches  
819 indicate SNPs numbers. (B) Estimation of the date of internal nodes using least-squares dating  
820 (<https://lsdating.pasteur.fr>) among the 4 strains isolated from the patient. Green bars represent the  
821 standard deviation of the estimated date.





822 **Figure 3.** Gene set enrichment analysis (GSEA) of biological process gene ontology terms across  
 823 pairwise comparisons of *Ye* proteomes. Positive normalized enrichment scores (NES) are shown in  
 824 red and correspond to enriched terms in the first strain in the comparison, while negative NES are  
 825 shown in blue and correspond to enriched term in the second strain in the comparison. Multiple  
 826 testing is adjusted by the Benjamini-Hochberg procedure.

827

828

**Table 1.** Minimum inhibitory concentration (mg/L) of the 4 Ye strains on 10 antibiotics and antibiotics combinations assessed by Etest.

<b>Antibiotic class</b>	<b>Antibiotic</b>	<b>Ye.1</b>	<b>Ye.2</b>	<b>Ye.3</b>	<b>Ye.4</b>
β-lactam	ceftriaxone <sup>123</sup>	0,047	0,094	0,094	>256
	cefoxitin	4	12	12	>256
	piperacillin-tazobactam <sup>3</sup>	0,094	0,25	<0,016	0,094
aminoglycosides and aminoglycosides-like	netilmicin <sup>12</sup>	0,75	3	0,06	0,06
	amikacin <sup>3</sup>	3	3	2	1
	tobramycin	1	1	0,09	0,09
	gentamicin	0,5	1	0,09	0,09
	spectinomycin	12	24	0,09	0,09
Quinolone	ciprofloxacin <sup>2</sup>	0,008	0,012	0,002	0,032
	levofloxacin	0,032	0,032	0,008	0,032

<sup>1</sup>Administred treatment between Ye.1 and Ye.2 isolation

<sup>2</sup>Administred treatment between Ye.2 and Ye.3 isolation

<sup>3</sup>Administred treatment between Ye.3 and Ye.4 isolation

**Table 2.** Small insertions/deletions and list of CDS absent in Ye.3 and Ye.4 strains' genome, along log2(foldchange) of protein abundance in all pairwise comparisons. Loci are expressed on Y11 reference genome. P-value and adjusted p-value can be found in Table S6. 0 corresponds to proteins not detected in any conditions of the comparison. 15 corresponds to proteins detected only in the first condition of the comparison.

Genbank id	Locus	Old locus	Status	Product	Ye.1	Ye.1	Ye.1	Ye.2	Ye.2	Ye.3
					vs	vs	vs	vs	vs	vs
					Ye.2	Ye.3	Ye.4	Ye.3	Ye.4	Ye.4
<b>Small insertions/deletions</b>										
WP_005165697.1	Y11_RS00200	Y11_00411	complete	NADP-dependent oxaloacetate-decarboxylating malate dehydrogenase MaeB	-0,26	0,35	1,72	0,61	1,97	1,37
WP_005164830.1	Y11_RS00450	Y11_00921	truncated	Glucokinase Glk	0,38	4,86	4,31	4,43	3,95	0
WP_013650157.1	Y11_RS01245	Y11_02641	complete	DNA topoisomerase (ATP-hydrolyzing) subunit A GyrA	0,06	-0,75	-0,25	-0,72	-0,96	-0,24
WP_005162896.1	Y11_RS01655	Y11_03551	complete	HAAAP family serine/threonine permease	-0,93	-0,81	0,7	0,12	1,63	1,51
WP_005158003.1	Y11_RS02570	Y11_05521	truncated	transcription-repair coupling factor Mfd	-0,02	3,35	3,19	3,38	3,21	-0,17
WP_112999146.1	Y11_RS02795	Y11_06001	truncated	sensor domain-containing diguanylate cyclase	0,44	1,32	15	0,82	15	0
WP_013649985.1	Y11_RS03165	Y11_06821	truncated	MFS transporter	1,2	15	15	15	15	0
WP_076706727.1	Y11_RS03165	Y11_06821	truncated	MFS transporter	1,2	15	15	15	15	0
WP_050344735.1	Y11_RS03400	Y11_07381	truncated	RNA chaperone ProQ	0,36	2,64	1,47	2,28	1,11	-1,17
WP_005165635.1	Y11_RS03825	Y11_08261	truncated	MATE family efflux transporter	0	0	0	0	0	0
WP_001534187.1	Y11_RS04455	Y11_09631	truncated	hypothetical protein	0	0	0	0	0	0
WP_145535939.1	Y11_RS04925	Y11_10641	truncated	type I DNA topoisomerase TopA	0,57	1,09	-0,12	0,52	-0,69	-1,21
WP_005157750.1	Y11_RS07710	Y11_16461	truncated	APC family permease	0	0	0	0	0	0
WP_005158842.1	Y11_RS08345	Y11_17791	truncated	urea ABC transporter ATP-binding subunit Urte	0	0	0	0	0	0
WP_145531626.1	Y11_RS08850	Y11_18831	truncated	two-component system sensor histidine kinase KdpD	-0,57	0,59	0,27	1,16	0,84	-0,32
WP_050879682.1	Y11_RS09025	Y11_19131	truncated	amino acid ABC transporter permease	3,16	15	15	15	15	0
WP_005167417.1	Y11_RS10470	Y11_22201	truncated	MFS transporter	0	0	0	0	0	0
WP_085910232.1	Y11_RS10470	Y11_22201	truncated	MFS transporter	0	0	0	0	0	0
WP_005163236.1	Y11_RS10625	Y11_22531	truncated	beta-ketoacyl-[acyl-carrier-protein] synthase family protein	0	0	0	0	0	0
WP_005163313.1	Y11_RS10785	Y11_22871	truncated	Aminopeptidase	0,67	2,46	1,95	1,78	1,27	-0,52
WP_005160711.1	Y11_RS11590	Y11_24591	truncated	hypothetical protein	0	0	0	0	0	0
WP_005180337.1	Y11_RS11725	Y11_24871	truncated	3',5'-cyclic-AMP phosphodiesterase - CpdA	1,49	2,66	2,09	1,17	0,63	0
WP_016266722.1	Y11_RS12715	Y11_26981	truncated	toxin subunit	0	0	0	0	0	0
WP_011815289.1	Y11_RS13360	Y11_28281	truncated	class II fructose-bisphosphatase GlpX	-0,55	3,5	2,93	4,05	3,47	-0,58
WP_005161086.1	Y11_RS14235	Y11_30151	truncated	DUF3748 domain-containing protein	0	0	0	0	0	0
WP_049679210.1	Y11_RS14685	Y11_31111	truncated	dipeptide transporter permease DppB	0	0	0	0	0	0
WP_019250468.1	Y11_RS14860	Y11_31471	truncated	inorganic phosphate transporter PitA	-0,31	15	0,61	15	1,02	0
WP_005157438.1	Y11_RS14960	Y11_31681	truncated	MurR/RpiR family transcriptional regulator	-0,2	1,81	2,63	2,01	2,83	0,82
WP_014609301.1	Y11_RS15690	Y11_33251	truncated	DUF494 domain-containing protein	0	0	0	0	0	0
WP_005181075.1	Y11_RS15890	Y11_33631	truncated	guanosine pentaphosphate phosphohydrolase/exopolyposphatase GppA	0,23	2,92	15	2,63	15	0
WP_005166113.1	Y11_RS16045	Y11_33921	truncated	DUF484 domain-containing protein	1,61	15	15	15	15	0
WP_005165794.1	Y11_RS16565	Y11_34951	complete	DNA-directed RNA polymerase subunit beta' RpoC	-0,1	-0,06	-0,41	0,05	-0,3	-0,35
WP_005156737.1	Y11_RS16685	Y11_35131	truncated	cation/acetate symporter ActP	-0,51	15	15	15	15	0
WP_005156732.1	Y11_RS16695	Y11_35151	truncated	acetate--CoA ligase Acs	-0,29	3,98	15	4,27	15	15
WP_011815418.1	Y11_RS17110	Y11_36011	truncated	miniconductance mechanosensitive channel MscM	-0,24	2,59	2,75	2,83	2,99	0,16
WP_005156285.1	Y11_RS17420	Y11_36641	truncated	23S rRNA (uridine(2552)-2'-O)-methyltransferase RlmE	0,36	15	2,4	15	2,09	0
WP_023160195.1	Y11_RS17940	Y11_37741	truncated	dihydroxyacetone kinase subunit DhaM	-0,65	1,25	0,66	1,91	1,31	-0,6
WP_004706052.1	Y11_RS18210	Y11_38281	complete	two-component system response regulator ArcA	0,65	0,37	0,17	-0,28	-0,48	-0,2
WP_049530647.1	Y11_RS18720	Y11_39351	truncated	TonB-dependent siderophore receptor	0	0	0	0	0	0
WP_005156741.1	Y11_RS18820	Y11_39571	truncated	RNA polymerase binding protein DksA	-0,03	4,47	4,42	4,51	4,46	-0,05
Y11_RS18810	Y11_39551	Y11_39551	deleted	hypothetical protein DJ62_2388						
Y11_RS18815	Y11_39561	Y11_39561	deleted							
<b>Large deletion of 9,919 bp (positions 887742 to 897661) - 9 genes</b>										
WP_072076553.1	Y11_RS03970	Y11_08571	deleted	dipeptide/tripeptide permease DtpA	0,45	15	15	15	15	0
WP_005166379.1	Y11_RS03975	Y11_08591	deleted	LysR family transcriptional regulator	-0,47	15	15	15	15	0
WP_005166377.1	Y11_RS03980	Y11_08601	deleted	oxidoreductase	0	0	0	0	0	0
WP_005178982.1			deleted	hypothetical protein						
WP_005166373.1	Y11_RS03990	Y11_08621	deleted	peptide ABC transporter ATP-binding protein SapF	-0,01	15	15	15	15	0
WP_005166371.1	Y11_RS03995	Y11_08631	deleted	peptide ABC transporter ATP-binding protein SapD	0,31	15	4,23	15	3,72	0
WP_005166369.1	Y11_RS04000	Y11_08641	deleted	peptide ABC transporter permease SapC	0	0	0	0	0	0
WP_005169521.1	Y11_RS04005	Y11_08651	deleted	peptide ABC transporter permease SapB	0	0	0	0	0	0
WP_005166365.1	Y11_RS04010	Y11_08661	deleted	peptide ABC transporter substrate-binding protein SapA	-0,14	15	15	15	15	0
<b>Large deletion of 32,673 bp (positions 1039738 to 1072411) - 28 genes</b>										
WP_005164789.1	Y11_RS04705	Y11_10131	deleted	DUF2813 domain-containing protein	0	0	0	0	0	0
YP_001006252.1	Y11_RS04710		deleted	type I secretion system permease/ATPase	0	0	0	0	0	0
WP_005164791.1	Y11_RS04720		deleted	HlyD family type I secretion periplasmic adaptor subunit	0	0	0	0	0	0
WP_005164793.1	Y11_RS04725	Y11_10171	deleted	peptidase C39	0	0	0	0	0	0
WP_023161026.1	Y11_RS04730	Y11_10191	deleted	formate--tetrahydrofolate ligase Fhs	-0,72	2,88	2,59	3,6	3,29	-0,3
WP_005164796.1	Y11_RS04735	Y11_10201	deleted	DUF2569 domain-containing protein	0	0	0	0	0	0
WP_005164797.1	Y11_RS04740	Y11_10211	deleted	electron transport complex subunit RxsA	0	0	0	0	0	0
WP_005164800.1	Y11_RS04745	Y11_10221	deleted	electron transport complex subunit RxsB	0	0	0	0	0	0
WP_014608949.1	Y11_RS04750	Y11_10231	deleted	electron transport complex subunit RxsC	0	0	0	0	0	0
WP_005164805.1	Y11_RS04755		deleted	hypothetical protein	0	0	0	0	0	0
WP_005164807.1	Y11_RS04760	Y11_10261	deleted	right oriC-binding transcriptional activator	0	0	0	0	0	0
WP_020283189.1	Y11_RS04765	Y11_10281	deleted	electron transport complex subunit RxsD	0	0	0	0	0	0
WP_005164811.1	Y11_RS04770	Y11_10291	deleted	electron transport complex subunit RxsG	-0,06	15	15	15	15	0
WP_005164813.1	Y11_RS04775	Y11_10301	deleted	electron transport complex subunit RxsE	-1,57	0	0	15	15	0
WP_005164815.1	Y11_RS04780	Y11_10311	deleted	endonuclease III Nth	0,39	15	4,92	15	4,54	0
WP_016266185.1	Y11_RS04785	Y11_10321	deleted	pore-forming cytotoxin subunit YaxB	-2,57	2,34	1,78	4,89	4,35	0
WP_005164820.1	Y11_RS04790	Y11_10331	deleted	alpha-xenorhabdolyisin family binary toxin YaxA	-2,49	2,11	2,38	4,6	4,87	0
WP_005166280.1	Y11_RS04805	Y11_10361	deleted	oxidoreductase	0	0	0	0	0	0
WP_005178976.1			deleted	hypothetical protein						
WP_005166281.1	Y11_RS04810	Y11_10381	deleted	exoribonuclease II Rnb	0,07	15	2,6	15	2,52	0
WP_005166282.1	Y11_RS04815	Y11_10401	deleted	carbon starvation protein A	2,39	2,34	15	-0,05	15	0
WP_005166289.1	Y11_RS04820		deleted	DUF466 domain-containing protein	0	0	0	0	0	0
WP_005166294.1	Y11_RS04825	Y11_10421	deleted	fructose-6-phosphate aldolase Fsa	-0,6	4,69	4,86	5,3	5,46	0,18
WP_005166295.1	Y11_RS04830	Y11_10431	deleted	DeoR/GlpR transcriptional regulator YciT	-0,65	15	15	15	15	0
WP_005166298.1	Y11_RS04835	Y11_10441	deleted	DUF2164 domain-containing protein	-0,77	15	15	15	15	0
WP_005166300.1	Y11_RS04840	Y11_10451	deleted	L-ribulose-5-phosphate 4-epimerase AraD	0	0	0	0	0	0
WP_005166303.1	Y11_RS04845	Y11_10461	deleted	glycine zipper 2TM domain-containing protein OsmB	0,87	15	15	15	15	0
WP_002224869.1			deleted	gluconate 5-dehydrogenase						
<b>Large deletion of 2,533 bp (positions 4134104 to 4136637) - 2 genes</b>										
WP_002228219.1	Y11_RS18810	Y11_39551	deleted	polynucleotide adenyltransferase PcnB	-0,08	4,28	4,13	4,37	4,21	0
WP_005156770.1	Y11_RS18815	Y11_39561	deleted	tRNA glutamyl-Q(34) synthetase GluQRS	-0,58	15	15	15	15	0

bioRxiv preprint doi: <https://doi.org/10.1101/2024.06.12.598599>; this version posted June 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



**Table 3.** Log2(foldchange) of the proteome pairwise comparisons for selected proteins. Proteins were mapped on the Y11 reference genome. P-value and adjusted p-value can be found in Table S6. 0 corresponds to proteins not detected in any conditions of the comparison. +15 and -15 corresponds to proteins detected only in the first or second condition of the comparison, respectively.

Locus	Old Locus	Gene	Product	Log2(foldchange)									
				Ye.1 vs Ye.2	Ye.1 vs Ye.3	Ye.1 vs Ye.4	Ye.2 vs Ye.3	Ye.2 vs Ye.4	Ye.3 vs Ye.4				
<b>Virulence-associated proteins</b>													
Y11_RS00110	Y11_00221	<i>ail</i>	attachment invasion locus protein Ail	0	2,62	3,25	2,63	3,25	0,62				
Y11_RS01220	Y11_02591	<i>eco</i>	serine protease inhibitor ecotin	-0,05	1,35	1,66	1,39	1,71	0,32				
Y11_RS06755	Y11_14481	<i>inv</i>	autotransporter invasin Inv	0,53	1,28	4,99	0,75	4,47	3,71				
Y11_RS01540	Y11_03301	<i>myfA</i>	fimbrial polyadhesin major subunit MyfA	-0,27	0,62	1,18	0,89	1,47	0,57				
Y11_RS01020	Y11_02141	<i>rovM</i>	virulence transcriptional regulator RovM	1,02	-1,57	-2,01	-2,59	-3,03	-0,44				
Y11_RS14390	Y11_30461	<i>sodA</i>	superoxide dismutase [Mn]	0,33	1,09	1,13	0,75	0,79	0,04				
Y11_RS03855	Y11_08321	<i>sodB</i>	superoxide dismutase [Fe]	0,06	1,73	1,96	1,67	1,91	0,23				
Y11_RS10840	Y11_22981	<i>sodC</i>	superoxide dismutase family protein [Cu-Zn]	0,7	3,08	3,5	2,38	2,8	0,42				
Y11_RS09565	Y11_20331	<i>ymoA</i>	expression modulating protein YmoA	-0,19	-2,41	-3	-2,22	-2,81	-0,59				
<b>Chemotaxis proteins</b>													
Y11_RS06745	Y11_14461	<i>flgM</i>	anti-sigma-28 factor FlgM	-0,56	-1,01	-1,56	-0,44	-1	-0,55				
Y11_RS06785	Y11_14551	<i>cheZ</i>	protein phosphatase CheZ	-0,6	-2,08	-2,86	-1,48	-2,26	-0,78				
Y11_RS06790	Y11_14561	<i>cheY</i>	chemotaxis response regulator CheY	-0,06	-1,74	-1,96	-1,68	-1,9	-0,22				
Y11_RS06795	Y11_14571		chemotaxis response regulator protein-glutamate methyltransferase	0	-0,34	-0,14	-0,85	-0,76	0,15				
Y11_RS06805	Y11_14591		methyl-accepting chemotaxis protein	0	-15	-15	-2,19	-2,48	-0,31				
Y11_RS06815	Y11_14621	<i>cheW</i>	chemotaxis protein CheW	0	-2,6	-3,26	-2,59	-3,26	-0,67				
Y11_RS06820	Y11_14641	<i>cheA</i>	chemotaxis protein CheA	0	-0,75	-2,55	-0,94	-2,71	-1,8				
Y11_RS11490	Y11_24361	<i>flgM</i>	flagellar biosynthesis anti-sigma factor FlgM	0,08	1,54	1,43	1,45	1,35	-0,11				
<b>Quorum sensing proteins</b>													
Y11_RS02270	Y11_04881	<i>yenR</i>	LuxR family transcriptional regulator YenR	-0,31	0,58	1,3	0	0	0				
Y11_RS02275	Y11_04891	<i>yenI</i>	acyl-homoserine-lactone synthase	-0,36	-2,42	-2,17	-2,06	-1,79	0,26				
Y11_RS10410	Y11_22111	<i>luxS</i>	S-ribosylhomocysteine lyase	-0,04	0,16	0,38	0,2	0,42	0,22				
Y11_RS17855	Y11_37571	<i>lsrG</i>	(4S)-4-hydroxy-5-phosphonooxypentane-2,3-dione isomerase	-0,3	1,2	1,94	1,49	2,23	0,74				
Y11_RS17860	Y11_37581	<i>lsrF</i>	3-hydroxy-5-phosphonooxypentane-2,4-dione thiolase	-0,51	2,05	2,68	2,56	3,18	0,62				
Y11_RS17865	Y11_37591	<i>lsrB</i>	autoinducer 2 ABC transporter substrate-binding protein LsrB	0,03	2,81	3,84	2,78	3,81	1,03				
Y11_RS17870	Y11_37601	<i>lsrD</i>	autoinducer 2 ABC transporter permease LsrD	0	0	0	0	0	0				
Y11_RS17880	Y11_37621	<i>lsrA</i>	autoinducer 2 ABC transporter ATP-binding protein LsrA	-0,45	15	15	15	15	0				
Y11_RS17885	Y11_37631	<i>lsrR</i>	transcriptional regulator LsrR	0,15	1,25	1,43	1,1	1,28	0,18				
Y11_RS17890	Y11_37641	<i>lsrK</i>	autoinducer-2 kinase	-0,15	0,81	1,3	0,96	1,45	0,49				
<b>Iron import and storage proteins</b>													
Y11_RS02915	Y11_06251	<i>fcuA</i>	Ferrichrome receptor protein FcuA	1,51	-0,54	-1,43	-2,04	-2,94	-0,9				
Y11_RS03015	Y11_06491	<i>ftnA</i>	non-heme ferritin	-0,27	1,46	2,04	1,73	2,31	0,58				
Y11_RS05035	Y11_10881	<i>tonB</i>	TonB system transport protein TonB	0,98	-1,07	-1,96	-2,05	-2,94	-0,89				
Y11_RS05710	Y11_12361		siderophore-interacting protein	0,76	-0,55	-1,22	-1,31	-1,98	-0,67				
Y11_RS08900	Y11_18931	<i>fur</i>	ferric iron uptake transcriptional regulator	-0,18	0,43	1,37	0,61	1,55	0,94				
Y11_RS11645	Y11_24711	<i>exbD</i>	TonB system transport protein ExbD	0,37	-1,41	-2,68	-1,78	-3,06	-1,28				
Y11_RS11650	Y11_24721	<i>exbB</i>	tol-pal system-associated acyl-CoA thioesterase	1,79	0,31	-0,86	-1,49	-2,65	-1,16				
Y11_RS15495	Y11_32861	<i>bfr</i>	bacterioferritin	0,68	3,87	4,66	3,19	3,98	0,79				
Y11_RS16005	Y11_33831	<i>hemY</i>	protoheme IX biogenesis protein HemY	0,13	1,29	1,56	1,17	1,44	0,27				
Y11_RS16010	Y11_33841	<i>hemX</i>	uroporphyrinogen-III C-methyltransferase	0,51	1,09	1,57	0,57	1,06	0,48				
Y11_RS16920	Y11_35641		TonB-dependent siderophore receptor	0,49	-2,35	-3,5	-2,84	-3,99	-1,15				
Y11_RS16930	Y11_35671	<i>hmuV</i>	Hemin import ATP-binding protein HmuV	0	0	0	0	0	0				
Y11_RS16935	Y11_35681	<i>hmuU</i>	Hemin transport system permease protein HmuU	0	0	0	0	0	0				
Y11_RS16940	Y11_35691	<i>hmuT</i>	hemin ABC transporter substrate-binding protein	0,88	-1,2	-2,82	-2,08	-3,7	-1,62				
Y11_RS16945	Y11_35701	<i>hmuS</i>	hemin-degrading factor	0,29	-2,71	-4,85	-2,99	-5,13	-2,14				
Y11_RS16950	Y11_35711	<i>hmuR</i>	TonB-dependent hemoglobin/transferrin/lactoferrin family receptor	1,85	-1,42	-2,95	-3,27	-4,79	-1,52				
Y11_RS18015	Y11_37891	<i>fecA</i>	Iron(III) dicitrate transport protein FecA	2	0,26	-0,74	-1,73	-2,75	-1,01				
<b>Beta-lactamase associated proteins</b>													
Y11_RS04605	Y11_09911	<i>blaA</i>	class A beta-lactamase BlaA	0,45	-1,37	-3,01	-1,83	-3,46	-1,63				
Y11_RS05870	Y11_12651	<i>blaB</i>	class C beta-lactamase BlaB (AmpC)	1,03	-0,03	-0,97	-1,05	-1,99	-0,94				
Y11_RS05875	Y11_12661	<i>ampR</i>	LysR family transcriptional regulator AmpR	0,46	-2,15	-0,65	-2,6	-1,11	1,49				
Y11_RS18675	Y11_39241	<i>ampD</i>	1,6-anhydro-N-acetylmuramyl-L-alanine amidase AmpD	0	-0,06	0,19	-0,15	0,05	0,24				
Y11_RS18680	Y11_39251	<i>ampE</i>	beta-lactamase regulator AmpE	-0,49	0,82	2,58	1,31	3,06	1,75				
<b>Porins</b>													
Y11_RS01275	Y11_02741	<i>ompC</i>	porin OmpC	-1,48	0,9	-0,15	2,38	1,34	-1,04				
Y11_RS02065	Y11_04441	<i>ompF</i>	porin OmpF	1,4	-1,37	3,58	-2,77	2,18	4,95				
Y11_RS02150	Y11_04631	<i>ompA</i>	porin OmpA	-0,24	0,53	0,26	0,77	0,5	-0,27				
Y11_RS05005	Y11_10821	<i>ompW</i>	outer membrane protein OmpW	0,92	-2,55	-1,52	-3,47	-2,44	1,03				
Y11_RS05640	Y11_12201		porin	1,22	-2,84	-2,99	-4,07	-4,19	-0,15				
Y11_RS08265	Y11_17621	<i>aqpZ</i>	aquaporin Z	-0,79	2,64	4,48	3,43	5,27	1,84				
Y11_RS08275	Y11_17651	<i>ompF2</i>	porin OmpF2	0,19	-0,96	-1,92	-1,15	-2,12	-0,96				
Y11_RS15180	Y11_32151	<i>ompR</i>	two-component system response regulator OmpR	-1,92	0,83	0,58	2,75	2,5	-0,25				
Y11_RS15185	Y11_32161	<i>envZ</i>	two-component system sensor histidine kinase EnvZ	-1,26	0,69	0	1,95	1,26	-0,69				
<b>Efflux pumps</b>													
Y11_RS00155	Y11_00321	<i>acrD</i>	multidrug efflux RND transporter permease AcrD	-0,54	-2,03	-0,85	-1,49	-0,31	1,18				
Y11_RS00315	Y11_00681	<i>macA</i>	macrolide-specific efflux protein MacA	0	-15	0	-15	0	1,4				
Y11_RS09485	Y11_20131	<i>acrR</i>	multidrug efflux transporter transcriptional repressor AcrR	0	0	0	0	0	0				
Y11_RS09490	Y11_20141	<i>acrA</i>	efflux RND transporter adaptor subunit AcrA	0,22	0,82	0,87	0,6	0,65	0,05				
Y11_RS09495	Y11_20151	<i>acrB</i>	efflux RND transporter permease AcrB	0,14	1,2	1,08	1,06	0,94	-0,11				
Y11_RS10240	Y11_21811	<i>emrA</i>	multidrug efflux MFS transporter periplasmic adaptor subunit EmrA	0	-0,33	-2,77	-0,39	-2,86	-2,45				
Y11_RS10245	Y11_21821	<i>emrB</i>	multidrug efflux MFS transporter permease subunit EmrB	0	0	0	0	0	0				
Y11_RS11740	Y11_24901	<i>tolC</i>	outer membrane channel protein TolC	0,05	-0,18	-0,18	-0,23	-0,23	0				
Y11_RS18200	Y11_38261	<i>robA</i>	MDR efflux pump AcrAB transcriptional activator RobA	-0,86	0,76	1,2	0,13	2,06	0,44				
Y11_RS20600	Y11_43311	<i>mdtC</i>	multidrug efflux RND transporter permease subunit MdtC	-0,16	-0,51	-0,37	-0,34	-0,21	0,14				
Y11_RS20605	Y11_43321	<i>mdtB</i>	MdtB/MuxB family multidrug efflux RND transporter permease subunit	-0,06	0,11	0,28	0,17	0,34	0,17				
Y11_RS20610	Y11_43331	<i>mdtA</i>	MdtA/MuxA family multidrug efflux RND transporter periplasmic adaptor subunit	-0,53	-0,64	-0,04	-0,12	0,49	0,61				

bioRxiv preprint doi: <https://doi.org/10.1101/2024.06.12.598599>; this version posted June 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.